WO1988002251A1 - Sunscreen compositions and compounds for use therein - Google Patents

Sunscreen compositions and compounds for use therein Download PDF

Info

Publication number
WO1988002251A1
WO1988002251A1 PCT/AU1987/000330 AU8700330W WO8802251A1 WO 1988002251 A1 WO1988002251 A1 WO 1988002251A1 AU 8700330 W AU8700330 W AU 8700330W WO 8802251 A1 WO8802251 A1 WO 8802251A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
alkoxy
formula
hydrogen
Prior art date
Application number
PCT/AU1987/000330
Other languages
French (fr)
Inventor
Graham Bird
Neil Fitzmaurice
Walter Clark Dunlap
Bruce Edward Chalker
Wickramasinghe Mudiyanselage Bandaranayake
Original Assignee
Ici Australia Operations Proprietary Limited
Australian Institute Of Marine Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Australia Operations Proprietary Limited, Australian Institute Of Marine Science filed Critical Ici Australia Operations Proprietary Limited
Priority to DE87906641T priority Critical patent/DE3788568T2/en
Priority to AT87906641T priority patent/ATE98863T1/en
Priority claimed from AU80728/87A external-priority patent/AU595075C/en
Publication of WO1988002251A1 publication Critical patent/WO1988002251A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms

Definitions

  • the invention relates to sunscreen compositions comprising ultra-violet radiation absorbing compounds to methods of preparing such compositions, and to UV-absorbing compounds of particular use in preparing such compositions.
  • Sunscreen compositions may be used to form a coating for protecting substrates from harmful effects of ultraviolet radiation such as in solar radiation.
  • sunscreen compositions are probably best known for use in the protection of skin against severe erythra edema which can be caused by exposure to sunlight.
  • UV-agents include, for example, para-aminobenzoic acid derivatives, benzotriazoles, benzophenones, methoxycinnamates and salicylates. It has been proposed, for example in U.K. Patent Application 2,120,549A and French Patent Application 8301391, that certain specific classes of vinylagous amide compounds (enaminoketones) may also be used as UV-absorbing sunscreen agents.
  • R 1 is selected from the group consisting of: C 1 to C 18 alkyl; C 1 to C 9 alkyl substituted with a substituent selected from the group of hydroxy, amino, C 1 to C 9 alkoxy, C 2 to C 9 alkenyloxy, C 1 to C 9 alkanoyl, (C 1 to C 9 alkoxy)carbonyl, carbamoyl, (C 1 to C 6 alkyl)carbamoyl and phenyl; C 2 to C 18 alkenyl; C 2 to C 9 alkenyl substituted with a substituent selected from the group consisting of hydroxy, amino, C 1 to C 9 alkoxy, C 2 to C 9 alkenyloxy, C 1 to C 9 alkanoyl, carbamoyl, (C 1 to C 6 alkyl)carbamoyl, and phenyl;C 2 to C 18 alkynyl; phenyl; the groups phenyl and benzyl said groups being substituted in the benzyl
  • R 1 may optionally link together with R 2 via a bridging group of formula -(R 7 R 8 C) m- wherein m is 2 or 3 and R 7 (which may be the same or different) and R 8 (which may be the same or different) are independently selected from the group of hydrogen and C 1 to C 6 alkyl;
  • R 3 is selected from the group consisting of: C 1 to C 18 alkyl; C 1 to C 9 alkyl substituted with a substituent selected from the group of amino, C 1 to C 9 alkoxy, C 2 to C 9 alkenyloxy, C 1 to C 9 alkanoyl, (C 1 to C 9 alkoxy)carbonyl, carbamoyl, (C 1 to C 9 alkyl)carbamoyl, and phenyl; C 2 to C 18 alkenyl; C 2 to C 9 alkenyl substituted with a substituent selected from the group consisting of hydroxy, amino C 1 to C 9 alkoxy, C 2 to C 9 alkenyloxy, C 1 to C 9 alkanoyl, (C 1 to C 9 alkoxy)carbonyl, carbamoyl, (C 1 to C 9 alkyl)carbamoyl and phenyl; C 2 to C 18 alkynyl; phenyl; benzoyl; the groups phenyl,
  • R (which may be the same or different) is a bivalent hydrocarbon radical of 2 to 6 (more preferably 2 to 4) carbon atoms and
  • R 9 is a hydrocarbon radical selected from C 1 to C 6 alkyl, C 2 to C 6 alkenyl, phenyl, benzyl, C 1 to C 6 alkyl phenyl and (C 1 to C 6 alkyl)benzyl (more preferably R 9 is selected from C 1 to C 4 alkyl and C 2 to C 4 alkenyl);
  • R 2 is selected from the group consisting of hydrogen, C 1 to C 6 alkyl, C 1 to C 6 alkoxy, and the group wherein R 1 and R 2 together form a bridging group of formula -(CR 7 R 8 ) m - wherein R 7 , R 8 and m are as hereinbefore defined;
  • R 4 is selected from the group consisting of
  • n is an integer selected from 0 to 4 inclusive;
  • R 5 and R 6 which may be the same or different are selected from hydrogen, C 1 to C 6 alkyl, C 1 to C 6 alkoxy, C 1 to C 10 alkanoyl, C 1 to C 10 alkanoyl substituted by carboxyl or (C 1 to C 6 alkoxy)carbonyl and wherein R 5 and R 6 may form a spiro-carbocyclic ring by the bridging group of formula II
  • R 10 and R 11 may be the same or different at each carbon unit of the bridge and are independently selected from hydrogen and C 1 to C 8 alkyl.
  • composition of the present invention may be applied to a surface to reduce the exposure of the surface to ultra-violet radiation.
  • the composition may be formulated, for example, as a solid, liquid, gel or aerosol and may generally comprise a carrier (extending medium) which adapts the agent for application to a surface.
  • a method of preparation of a sunscreen composition comprising mixing at least one compound of formula I with a carrier suitably adapted to allow application of said compound to a surface.
  • suitable carriers may include oils for example, mineral oils, paraffin, squalene and octyl palmetate and oil/alcohol mixtures.
  • At least one compound of formula I is combined with a water-insoluble liquid such as a paraffin oil to give an oil phase which is combined with an aqueous phase to form an oil-in-water emulsion in the presence of a suitable emulsifier.
  • a water-insoluble liquid such as a paraffin oil
  • the temperature at which the composition is formed is not critical and may be selected in accordance with the nature of to the components thereof. The temperature is typically in the range 0 to 150°C (preferably 0 to 80°) although higher or lower temperatures may be used if desired.
  • Further components such as perfumes, colouring agents, antioxidants and oxygen scavengers may be used in the composition of the present invention. Examples of oxygen scavengers include compounds which in the presence of oxygen are oxidised more readily than the compound of formula I. An example of an oxygen scavenger is sodium thiosulphate.
  • the composition may comprise additives making the composition useful as a cosmetic or phamaceutical.
  • One or more compounds of formula I may be utilized in the composition of the present invention and generally the concentration of said compound(s) is in the range of 0.5 to 20% by weight of the total composition. However higher or lower concentrations may be used if desired depending on the degree of screening required.
  • R 1 is selected from C 1 to C 18 alkyl;
  • R 3 is selected from C 1 to C 18 alkyl; C 1 to C 9 alkyl substituted with a substituent selected form the group consisting of hydroxy, amino, C 1 to C 9 alkoxy and C 1 to C 9 alkanoyl; C 2 to C 18 alkenyl; cyclohexyl; phenyl; benzyl; benzoyl; the groups phenyl, benzyl and benzoyl said groups being substituted in the benzene ring with a substituent selected from the group of C 1 to C 9 alkyl, C 2 to C 9 alkenyl, C 1 to C 9 alkoxy, C 1 to C 9 alkylamino, N,N-di(C 1 to C 6 alkyDamino, C 1 to C 9 alkanoyl and (C 1 to C 9 alkoxy)carbonyl; C 1 to C 18 alkanoyl; and C 2 to C 9 alkanoyl substituted with phenyl;
  • R 2 is selected from hydrogen and C 1 to C 6 alkyl; and wherein R 2 may link together with R 1 to form a bridging group of formula -CH 2 (R 7 R 8 OCH 2 - wherein R 7 and R 8 are independently selected from hydrogen and C 1 to C 6 alkyl;
  • R 4 is C 1 to C 6 alkyl; and n is from 0 to 4, and
  • R 5 and R 6 are independently selected from hydrogen; the group of formula III
  • R 10 and R 11 are independently selected from C 1 to C 4 alkyl and hydrogen; and R 12 is selected from hydrogen and C 1 to C 6 alkyl and wherein R 5 and R 6 may form a spiro-carbocyclic ring by the bridging group of formula II (a)
  • R 10 and R 11 are independently selected from hydrogen and C 1 to C 4 alkyl.
  • R 5 and R 6 are independently selected from hydrogen and C 1 to C 4 alkyl.
  • one of R 5 and R 6 is the group of formula III then the other is hydrogen.
  • compositions of the invention comprise at least one compound of formula I wherein:
  • R 1 is selected from the group consisting of C 1 to C 18 alkyl; C 1 to C 18 alkenyl; phenyl; and benzyl;
  • R 2 is hydrogen or C 1 to C 4 alkyl
  • R 2 may form a carbocyclic ring by the bridging group of formula
  • R 7 and R 8 are independently selected from hydrogen and C 1 to C 4 alkyl
  • R 3 is selected from C 2 to C 18 alkyl; C 1 to C 9 alkyl substituted with a substituent selected from the group consisting of hydroxy and C 1 to C 9 alkoxy; C 1 to C 18 alkenyl; benzoyl; benzyl; benzoyl substituted with a substituent selected from C 1 to C 6 alkyl and C 1 to C 6 alkoxy; and C 1 to C 9 alkanoyl; R 4 is C 1 to C 4 alkyl n is from 0 to 3
  • R 5 and R 6 are selected such that they comply with one of the possibilities selected from the group consisting of (i) R 5 and R 6 are independently selected from hydrogen and C 1 to C 4 alkyl; (ii) one of R 5 and R 6 is hydrogen and the other is a group of formula III
  • R 10 , R 11 and R 12 are independently selected from the group consisting of hydrogen and C 1 to C 4 alkyl; and (iii) the group wherein R 5 and R 6 form a spiro carbocyclic ring by the group of formula Ila
  • R 10 and R 11 are independently selected from the group consisting of hydrogen and C 1 to C 4 alkyl.
  • the compound of formula I is selected such that
  • R 1 is selected from the group consisting of C 1 to
  • R 2 is hydrogen or C 1 to C 4 alkyl; and wherein R 1 and R 2 may form a carbocyclic ring by the bridging group of formula
  • R 7 and R 8 are independently selected from hydrogen and C 1 to C 4 alkyl
  • R 3 is selected from C 1 to C 18 alkyl
  • R is C 1 to C 4 alkyl; n is from 0 to 3; and
  • R 5 and R 6 are independently selected from hydrogen and C 1 to C 4 alkyl.
  • compositions of the inventions are novel compounds .
  • R 1 is selected from the group consisting of: C 1 to C 18 alkyl; C 1 to C 9 alkyl substituted with a substituent selected from the group of hydroxy, amino, C 1 to C 9 alkoxy, C 2 to C 9 alkenyloxy, C 1 to C 9 alkanoyl, (C 1 to C 9 alkoxy)carbonyl, carbamoyl, (C 1 to C 6 alkyl)carbamoyl and phenyl; C 2 to C 18 alkenyl; C 2 to C 9 alkenyl substituted with a substituent selected from the group consisting of hydroxy, amino, C 1 to C 9 alkoxy, C 2 to C 9 alkenyloxy, C 1 to C 9 alkanoyl, carbamoyl, (C 1 to C 9 alkyl)carbamoyl, and phenyl; C 2 to C 18 alkynyl; phenyl; the groups phenyl and benzyl said groups being substituted in the benzene
  • R 4 is selected from the group consisting of C 1 to C 6 alkyl and C 1 to C 6 alkoxy; n is an integer selected from 0 to 4 inclusive; and R 5 and R 6 which may be the same or different are selected from hydrogen, C 1 to C 6 alkyl, C 1 to C 6 alkoxy C 1 to C 10 alkanoyl, C 1 to C 10 alkanoyl substituted by carboxyl or (C 1 to C 6 alkoxy)carbonyl and wherein R 7 and R 8 may form a spiro-carbocylic ring by the bridging group of formula II
  • R 3 is not selected from the group of benzyl, hydroxyethyl and methoxymethyl.
  • the substituents R 1 and/or R 3 may be a polymer of one or more of the monomers selected from ethylene glycol, propylene glycol and C 2 to C 4 alkenes and derivatives thereof. Examples of the derivatives may include derivatives comprising at least one group of formula XI (a) or XI (b)
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and n are as hereinbefore defined.
  • examples of derivatives thereof may include ethers formed by a bond of the terminal oxygen with a radical selected from the group of C 1 to C 6 alkyl, phenyl, benzyl, and the groups phenyl and benzyl substituted in the benzene ring with C 1 to C 9 alkyl.
  • the polymers contain in the range of from 3 to 18 monomeric units.
  • R 1 is selected from C 1 to C 18 alkyl; C 2 to C 9 alkyl substituted with a substituent selected from the group consisting of hydroxy, amino, C 1 to C 9 alkoxy, C 1 to C 9 alkanoyl and (C 1 to C 9 alkoxy)carbonyl; C 1 to C 18 alkenyl; cyclohexyl; phenyl; benzyl; the groups phenyl and benzyl said groups being substituted in the benzene ring with a substituent selected from the group of C 1 to C 9 alkyl, C 2 to C 9 alkenyl, C 1 to C 9 alkoxy, C 1 to C 9 alkanoyl and (C 1 to C 9 alkoxy)carbonyl; and wherein R 1 may optionally link together with R 2 by the a bridging group of formula -CH 2 (R 7 R 8 C)CH 2 - wherein R 7 and R are independently selected from hydrogen and C 1 to
  • R 4 is C 1 to C 6 alkyl; n is from 0 to 4; and
  • R 5 and R 6 are independently selected from hydrogen; the group of formula III
  • R 10 , R 11 and R 12 are independently selected fromC 1 to C 4 alkyl and hydrogen; and wherein R 5 and R 6 may form a spiro-carbocyclic ring by the bridging group of formula II (a)
  • R 10 and R 11 are independently selected from hydrogen and C 1 to C 4 alkyl.
  • R 5 and R 6 are independently selected from hydrogen and C 1 to C 4 alkyl.
  • one of R 5 and R 6 is the group of formula III then the other is hydrogen.
  • R 1 is selected from C 1 to C 18 alkyl; C 1 to C 6 alkyl substituted with a substituent selected from C 1 to C 6 alkanoyl and (C 1 to C 6 alkoxy)carbonyl; C 1 to C 18 alkenyl; phenyl; and benzyl;
  • R 2 is selected from hydrogen and C 1 to C 4 alkyl and wherein R 1 and R 2 may form a carbocyclic ring by the bridging group of formula
  • R 7 and R 8 are independently selected from hydrogen and C 1 to C 4 alkyl.
  • R 3 is selected from C 2 to C 18 alkyl; C 1 to C 9 alkyl substituted with a substituent selected from the group consisting of hydroxy and C 1 to C 9 alkoxy; C 1 to C 18 alkenyl; benzoyl; benzyl; benzoyl substituted with a substituent selected from C 1 to C 6 alkyl and C 1 to C 6 alkoxy; and C 3 to C 9 alkanoyl;
  • R 4 is C 1 to C 4 alkyl; n is from 0 to 3; and
  • R 5 and R 6 are selected such that they comply with one of the possibilities selected from the group consisting of (i) R 5 and R 6 are independently selected from hydrogen and C 1 to C 4 alkyl; (ii) one of R 5 and R 6 is hydrogen and the other is a group of formula III
  • R 10 , R 11 and R 12 are independently selected from hydrogen and C 1 to C 4 alkyl; and (iii) the group wherein R 5 and R 6 form a spiro carbocyclic ring by the diradical group of formula Ila
  • R 10 to R 11 are independently selected from hydrogen and C 1 to C 4 alkyl.
  • R 1 is C 1 to C 9 alkyl
  • R 2 is selected from hydrogen and C 1 to C 4 alkyl
  • R 1 and R 2 may form a carbocyclic ring by the bridging group of formula
  • R 8 and R 9 are methyl;
  • R 3 is selected from C 2 to C 9 alkyl, C 2 to C 9 alkenyl;
  • R 4 is selected from C 1 to C 4 alkyl; n is from 0 to 3;
  • R 5 and R 6 are selected such that they comply with one of the possibilities selected from the group consisting of (i) R 5 and R 6 are independently selected from hydrogen and C 1 to C 4 alkyl; (ii) one of R 5 and R 6 is hydrogen and the other is a group of formula III
  • R 10 and R 11 are methyl and R 12 is hydrogen or C 1 to C 4 alkyl; and (iii) the group wherein R 5 and R 6 form a spiro carbocyclic ring by the diradical group of formula II a
  • R 10 and R 11 are methyl.
  • R 5 and R 6 are not hydrogen or C 1 to C 4 alkyl then n is zero.
  • R 1 is seleted from the group consisting of methyl, ethyl, propyl and 4-methylbutyl;
  • R 2 is hydrogen or methyl; and wherein R 1 and R 2 may form a carbocyclic ring by the bridging group of formula:
  • R 7 and R 8 are methyl
  • R 3 is selected from the group consisting of:C 1 to C 9 alkyl such as
  • propyl butyl, 1-methylethyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, hexyl, 2-ethylhexyl, 1-methylpentyl, 1,1-dimethylbutyl, octyl, 1-methylheptyl and 3-methyl-2-butenyl; 2-phenylethyl; benzoyl, 3-methoxybenzoyl; 4-butylbenzoyl; propanoyl; benzyl;and cyclohexyl;
  • R 4 is methyl; n is chosen from 0 to 3 and is conveniently zero.
  • R 5 and R 6 are selected such that they comply with one of the possibilities selected from the group consisting of (i) R 5 and R 6 are independently selected from hydrogen and methyl; (ii) one of R 5 and R 6 is hydrogen and the other is a group of formula III
  • R 10 and R 11 are methyl and R 12 is ethyl; and (iii) the group wherein R 5 and R 6 form a spiro carbocyclic ring by the diradical group of formula IIa. II a wherein R 10 and R 11 are methyl.
  • One group of compounds of the invention which may be used in preparation of sunscreen compositions include compounds of formula la
  • R 3 , R 4 ,R 5 and R 6 are as hereinbefore defined in relation to compounds of the invention, R 13 is C 1 to
  • Preferrred compounds of formula la include compounds of formula I (a) (i)
  • R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and n are as hereinbefore defined.
  • R 5 and R 6 are compounds where R 5 and R 6 are independently selected from hydrogen, C 1 to C 6 alkyl and C 1 to C 6 alkoxy, preferably from hydrogen and C 1 to C 6 alkyl; more preferably from hydrogen and C 1 to C 4 alkyl such as methyl; and R 1 , R 2 , R 3 , R 4 and n are as hereinbefore defined.
  • such compound include compounds wherein R 1 is selected from the group consisting of methyl, ethyl, propyl, 3-methylbutyl; R 2 is hydrogen; R 3 is selected from the group consisting of propyl,
  • n 0; and R 5 and R 6 are hydrogen.
  • the compounds of formula 1(a) (i) include such compounds wherein R 5 and R 6 are hydrogen and R 3 is as hereinbefore defined and n is 0, that is the compounds of formula 1(a) (ii)
  • R 7 and R 8 are as hereinbefore defined.
  • R 5 and R 6 comprise the groups of formula III or formula Ila it is preferred that R 7 is identical with the group R 10 and R 5 is identical with the group R 11 .
  • Specific examples of compounds embraced by the invention include.
  • the compounds of formula I may be prepared by a variety of methods and in a further aspect of the invention there is provided methods for the preparation of compounds of the invention of formula I.
  • the compounds may generally be derived via a suitable tetrahydropyridine compound of formula IV or via a pyridine derivative of formula V (wherein A are independently selected from hydrogen and R 4 ).
  • the preparation of the compound of formula I from the pyridine derivative of formula V may be carried out by reduction of the compound of formula V for example using hydrogen in the presence of a catalyst (such as palladivim on charcoal catalyst) to give a compound of the invention of formula I(c).
  • a catalyst such as palladivim on charcoal catalyst
  • the pyridine derivative of formula V may be prepared from the compound of formula VII (wherein A
  • the preparation of a compound of formula I from the compound of formula IV may be carried out by reacting the compound of formula IV, preferably in the presence of a base, with a compound of formula VI wherein L is a leaving group.
  • the compound of formula IV having the specific formula IVa may be prepared by reduction of the pyridine of formula VII, for example using hydrogen in the presence of a catalyst such as palladium on charcoal.
  • the compound of formula IV (having the specific formula IVb) may be prepared by chemical reduction of the compound of formula VIII
  • A which may be the same or different is chosen from hydrogen or R 4 as hereinbefore defined.
  • N C-(CR 5 R 6 )CA 2
  • (L) may be chosen by those skilled in the art.
  • Examples of leaving groups include chloride, bromide, iodide, sulfate, nitrate, methylsulfate, ethylsulfate, tetrafluoroborate, hexafluorophosphate, hexafluoro- antiminate, methanesulfonate, fluorosulfonate, fluoromethanesulfonate and trifluoromethanesulfonate.
  • An alternative method of preparation of the compound of formula IV may involve reaction of the compound of formula XII with a compound of formula XIII in the presence of a base such as an amine to give the compound of formula XIV and hydrogenation of the compound of formula XIV to give the compound of formula IV(c) which may be converted as herein before described to a compound of the invention of formula I having the specific formula Kb).
  • a preferred example of this alternative method is the reaction of the compound of Xlll with mesityl oxide to give the compound of formula IV which has the formula XV which may be utilised in providing compounds of formula I having & 4, 4, 6-trimethyl substitution in the tetrahydro pyridine ring, for example, the compound methyl 1-butyl-4,4,6-trimethyl-1, 4,5, 6-tetrahydro-3-pyridyl ketone.
  • compositions of the present invention are particularly useful for protection of human skin against harmful effects of sunlight.
  • Human skin is well known to be sensitive to sunlight containing radiation of wavelengths between about 270 nm and 400 nm.
  • the OV-B region of ultra violet radiation (290-320 nm) has long been known to cause damage to skin but more recently concern has been expressed over the effect of UV-A radiation (above 320 nm).
  • compositions of the present invention may be prepared comprising one or more compounds of formula I and may provide screening in the UV-A region, the UV-B region or in both of these regions. Consequently, in one embodiment of the invention there is provided a method of protecting skin from ultra-violet radiation, the method comprising applying to the surface of the skin a composition as hereinbefore described.
  • a specific example of a sunscreen formulation which may be used in preparation of compositions of the present invention includes the following Sunscreen lotion composition % w/w
  • 3-acetyl-1,4,5,6-tetrahydropyridine was prepared by hydrogenation of 3-acetyl pyridine in the presence of palladium on carbon according to the method of Freifelder, J.Org.Chem. 29, 2895 (1964).
  • Methyl 1-propyl-1 ,4 ,5, 6-tetrahydro-3-pyridyl ketone was prepared from 3-acetyl-1 , 4 , 5 , 6- tetrahydropyridine and 1-bromopropane according to the procedure of Part b) of Example 1.
  • the product distilled as a pale yellow (b.pt98-100°C/0.5 mm Hg) .
  • Methyl 1-(3-methylbutyl)-1,4,5,6-tetrahydro-3- pyridyl ketone was prepared from 3-acetyl-414,5,6- tetrahydropyridine and 1-bromo-3-methylbutane according to the procedure of Part b) of Example 1.
  • the product distilled as a pale yellow oil (b.pt. 103-106°C/0.1 mm Hg).
  • Methyl 1-benzoyl-1,4,5,6-tetrahydro-3-pyridyl ketone was prepared from 3-acetyl-1,4,5,6- tetrahydropyridine and benzoyl chloride according to the procedure of Part b) of Example 1.
  • the product was recrystallised from ethanol/water m.pt. 93-95°C.
  • Example 4 Part a) of Example 4 to give 1-(2-propenyl)- 3-butyryl pyridium bromide as a cream coloured crystalline solid.
  • Example 6 Part a) of Example 6 to give 1-butyl-3- butyryl pyridinium bromide as a tan coloured crystalline solid.
  • the aqueous layer was neutralised to pH9 with aqueous sodium hydroxide solution and extracted with diethyl ether (3 x 100 ml).
  • the organic phase was dried (magnesium sulphate), concentrated under reduced pressure and distilled to give 3-methylbutyl 3-pyridyl ketone.
  • Example 1 to give 7,7-dimethyl-1,2,3,4,7,8- hexahydro-1-benzoyl-quinolin-5(6H)-one(19) as a yellow solid.
  • Example 23 The reaction solution of Example 23 consisting of 5,5-dimethyl-3-hexylaminocyclohex-2-enone (26.76g; 0.12 mole), aqueous formaldehyde (37% w/w; 9 ml) and 2N hydrochloric acid (40 ml) was refluxed for 5 h.
  • the reaction mixture was chilled on ice, made basic with 2N NH.OH, extracted into chloroform (3 x 100 ml) and dried over MgSO 4 .
  • Example 25 - 35 of the invention were prepared by the general method described in Example 23 or Example 24 and are listed in Table I where the R 3 group is defined as the 1-substituent. TABLE 1
  • the compounds of Examples 1 to 24 inclusive were characterised by, and can be identified by their 'H nuclear magnetic resonance spectra.
  • the 'H nuclear magnetic resonance spectra for the compounds of Examples 1 to 23 are recorded in Table 2 below Table 2.
  • compositions were prepared using a mixture of part A, B and C for each of compounds 3, 5, 13 and 18 as the effective component.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

Certain compounds of formula (I) and sunscreen compositions comprising as an effective component at least one compound of formula (I), wherein R1 is selected from alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, phenyl, substituted phenyl, substituted benzyl, cycloalkyl, cycloalkenyl, substituted cycloalkyl, substituted cycloalkenyl and polymeric groups; R2 is selected from hydrogen, alkyl and alkoxy; and wherein R1 and R2 may form a carbocyclic ring which may be substituted; R3 is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, phenyl, benzoyl, substituted phenyl, substituted benzyl, substituted benzoyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, alkanoyl, substituted alkanoyl, polymeric groups, the group OROROR9 wherein R is a bivalent hydrocarbon radical and R9 is alkyl, alkenyl, phenyl, benzyl, substituted phenyl, substituted benzyl; R4 is alkyl or alkoxy; n is an integer from 0 to 4; and R5 and R6 are independently selected from alkyl, alkoxy, alkanoyl, alkanoyl substituted by hydroxyl or alkoxycarbonyl and R5 and R6 may form a spiro carbocyclic ring which may be substituted with alkyl.

Description

SUNSCREEN COMPOSITIONS AND COMPOUNDS FOR USE THEREIN
The invention relates to sunscreen compositions comprising ultra-violet radiation absorbing compounds to methods of preparing such compositions, and to UV-absorbing compounds of particular use in preparing such compositions. Sunscreen compositions may be used to form a coating for protecting substrates from harmful effects of ultraviolet radiation such as in solar radiation. For example, sunscreen compositions are probably best known for use in the protection of skin against severe erythra edema which can be caused by exposure to sunlight.
Common commercially available UV-agents include, for example, para-aminobenzoic acid derivatives, benzotriazoles, benzophenones, methoxycinnamates and salicylates. It has been proposed, for example in U.K. Patent Application 2,120,549A and French Patent Application 8301391, that certain specific classes of vinylagous amide compounds (enaminoketones) may also be used as UV-absorbing sunscreen agents.
We have observed that certain mycosporinβ amino acids which exist in the living tissue of the Pacific staghem coral Acrooora formosa are functional UV-absorbing agents (λmax 310-332 nm) in corals inhabiting the shallow-water, tropical coral reef environment. While these naturally occurring enaminoketone compounds appear to be potentially attractive as commercial UV-agents, their utility is questionable because of the difficulty of isolating them from their biological source and because of their lack of adequate chemical stability. We have proposed that certain synthetic vinylagous amide analogues of those natural products can be prepared which preserves their characteristic UV-absorbing chromophore within a chemically more stable structure and which typically have UV-absorption maxima (λmax) in the wavelength region 288-340 nanometers (P.C.T. Patent Application PCT/AU85/00242). These synthetic analogues, however, proved to be chemically unstable during prolonged period of formulation and storage. We have now found that a select group of cyclic vinylogous amide compounds which comprise a tetrahydropyridine moiety are particularly suitable for use in sunscreen compositions.
Accordingly we provide a sunscreen composition comprising as an effective component thereof at least one compound of formula I
wherein:
Figure imgf000004_0001
R1 is selected from the group consisting of: C1 to C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group of hydroxy, amino, C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl, (C1 to C9 alkoxy)carbonyl, carbamoyl, (C1 to C6 alkyl)carbamoyl and phenyl; C2 to C18 alkenyl; C2 to C9 alkenyl substituted with a substituent selected from the group consisting of hydroxy, amino, C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl, carbamoyl, (C1 to C6 alkyl)carbamoyl, and phenyl;C2 to C18 alkynyl; phenyl; the groups phenyl and benzyl said groups being substituted in the benzene ring with a substituent is selected from the group of C1 to C12 alkyl, C1 to C12 alkoxy, C1 to C12 alkenyloxy, C1 to C12 alkylamino, N,N-di(C1 to C6 alkyl)amino, (C1 to C12 alkoxy)carbonyl and C1 to C12 alkanoyl; C5 to C7 cycloalkyl; C5 to C7 cycloalkenyl; the groups substituted C5 to C7 cycloalkyl and substituted C5 to C7 cycloalkenyl wherein the substituent is selected from the group of hydroxy, amino, C1 to C9 alkyl, C1 to C9 alkoxy, and C1 to C9 alkenyloxy; polymers of one or more of the monomers selected from ethylene glycol, propylene glycol, styrene and
C2 to C4 alkenes, and derivatives of said polymers; and wherein R1 may optionally link together with R2 via a bridging group of formula -(R7R8C)m- wherein m is 2 or 3 and R7 (which may be the same or different) and R8 (which may be the same or different) are independently selected from the group of hydrogen and C1 to C6 alkyl;
R3 is selected from the group consisting of: C1 to C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group of amino, C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl, (C1 to C9 alkoxy)carbonyl, carbamoyl, (C1 to C9 alkyl)carbamoyl, and phenyl; C2 to C18 alkenyl; C2 to C9 alkenyl substituted with a substituent selected from the group consisting of hydroxy, amino C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl, (C1 to C9 alkoxy)carbonyl, carbamoyl, (C1 to C9 alkyl)carbamoyl and phenyl; C2 to C18 alkynyl; phenyl; benzoyl; the groups phenyl, benzyl and benzoyl said group being substituted in the benzene ring with a substituent selected from the group of hydroxy, amino, C1 to C12 alkyl, C2 to C12 alkenyl, C1 to C12 alkoxy, C2 to C12 alkenyloxy, C1 to C12 alkylamino, N,N-di(C1 to C6 alkyl)amino, (C1 to C12 alkoxy)carbonyl, and C1 to C12 alkanoyl; C5 to C7 cycloalkyl; C5 to C7 cycloalkenyl; the groups substituted C5 to C7 cycloalkyl and substituted C5 to C7 cycloalkenyl wherein the substituent is selected from the group of hydroxy, amino, C1 to C9 alkyl, C1 to C9 alkoxy, and C1 to C9 alkenyloxy; C1 to C18 alkanoyl; C2 to C9 alkanoyl substituted with a substituent selected from the group of hydroxy, amino, C1 to C9 alkoxy and C2 to C9 alkenyloxy, C1 to C9 alkanoyl; carbamoyl, (C1 to C6 alkyl)carbamoyl, (C1 to C9 alkoxy)carbonyl and phenyl; polymers of one or more monomers selected from ethylene glycol, propylene glycol, styrene and
C2 to C4 alkenes, and derivatives of said polymers; and the group -ORORO R9 wherein R (which may be the same or different) is a bivalent hydrocarbon radical of 2 to 6 (more preferably 2 to 4) carbon atoms and
R9 is a hydrocarbon radical selected from C1 to C6 alkyl, C2 to C6 alkenyl, phenyl, benzyl, C1 to C6 alkyl phenyl and (C1 to C6 alkyl)benzyl (more preferably R9 is selected from C1 to C4 alkyl and C2 to C4 alkenyl);
R2 is selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, and the group wherein R1 and R2 together form a bridging group of formula -(CR7R8)m- wherein R7, R8 and m are as hereinbefore defined;
R4 is selected from the group consisting of
C1 to C6 alkyl and C1 to C6 alkoxy; n is an integer selected from 0 to 4 inclusive; and
R5 and R6 which may be the same or different are selected from hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, C1 to C10 alkanoyl, C1 to C10 alkanoyl substituted by carboxyl or (C1 to C6 alkoxy)carbonyl and wherein R5 and R6 may form a spiro-carbocyclic ring by the bridging group of formula II
II
Figure imgf000007_0001
wherein q is 2 or 3 and R10 and R11 may be the same or different at each carbon unit of the bridge and are independently selected from hydrogen and C1 to C8 alkyl.
The composition of the present invention may be applied to a surface to reduce the exposure of the surface to ultra-violet radiation. The composition may be formulated, for example, as a solid, liquid, gel or aerosol and may generally comprise a carrier (extending medium) which adapts the agent for application to a surface.
In a further embodiment of the invention, there is provided a method of preparation of a sunscreen composition comprising mixing at least one compound of formula I with a carrier suitably adapted to allow application of said compound to a surface. Examples of suitable carriers may include oils for example, mineral oils, paraffin, squalene and octyl palmetate and oil/alcohol mixtures.
In a specific example, at least one compound of formula I is combined with a water-insoluble liquid such as a paraffin oil to give an oil phase which is combined with an aqueous phase to form an oil-in-water emulsion in the presence of a suitable emulsifier. The temperature at which the composition is formed is not critical and may be selected in accordance with the nature of to the components thereof. The temperature is typically in the range 0 to 150°C (preferably 0 to 80°) although higher or lower temperatures may be used if desired. Further components such as perfumes, colouring agents, antioxidants and oxygen scavengers may be used in the composition of the present invention. Examples of oxygen scavengers include compounds which in the presence of oxygen are oxidised more readily than the compound of formula I. An example of an oxygen scavenger is sodium thiosulphate. The composition may comprise additives making the composition useful as a cosmetic or phamaceutical.
One or more compounds of formula I may be utilized in the composition of the present invention and generally the concentration of said compound(s) is in the range of 0.5 to 20% by weight of the total composition. However higher or lower concentrations may be used if desired depending on the degree of screening required. Preferably in the compound of formula I R1 is selected from C1 to C18 alkyl;
C1 to C9 alkyl substituted with a substitutent selected from the group consisting of, hydroxy, amino, C1 to C9 alkoxy; C1 to C9 alkanoyl and (C1 to C9 alkoxy)carbonyl; C1 to C18 alkenyl; cyclohexyl; phenyl; benzyl; the groups phenyl and benzyl said groups being substituted in the benzene ring with a substituent selected form the group of C1 to C9 alkyl, C2 to C9 alkenyl, C1 to C9 alkoxy, C1 to C9 alkylamino, N,N-di(C1 to C6 alkyl)amino, C1 to C9 alkanoyl and (C1 to C9 alkoxy)carbonyl; and wherein R 1 may optionally link together with R2 via a bridging group of formula -CH2(R7R8OCH2- wherein R7 and R8 are independently selected from hydrogen and C1 to C6 alkyl;
R3 is selected from C1 to C18 alkyl; C1 to C9 alkyl substituted with a substituent selected form the group consisting of hydroxy, amino, C1 to C9 alkoxy and C1 to C9 alkanoyl; C2 to C18 alkenyl; cyclohexyl; phenyl; benzyl; benzoyl; the groups phenyl, benzyl and benzoyl said groups being substituted in the benzene ring with a substituent selected from the group of C1 to C9 alkyl, C2 to C9 alkenyl, C1 to C9 alkoxy, C1 to C9 alkylamino, N,N-di(C1 to C6 alkyDamino, C1 to C9 alkanoyl and (C1 to C9 alkoxy)carbonyl; C1 to C18 alkanoyl; and C2 to C9 alkanoyl substituted with phenyl;
R2 is selected from hydrogen and C1 to C6 alkyl; and wherein R2 may link together with R1 to form a bridging group of formula -CH2(R7R8OCH2- wherein R7 and R8 are independently selected from hydrogen and C1 to C6 alkyl;
R4 is C1 to C6 alkyl; and n is from 0 to 4, and
R5 and R6 are independently selected from hydrogen; the group of formula III
III
Figure imgf000009_0001
R10 and R11 are independently selected from C1 to C4 alkyl and hydrogen; and R12 is selected from hydrogen and C1 to C6 alkyl and wherein R5 and R6 may form a spiro-carbocyclic ring by the bridging group of formula II (a)
II (a)
Figure imgf000010_0001
wherein R10 and R11 are independently selected from hydrogen and C1 to C4 alkyl. Preferably wherein one of R5 and R6 is the group of formula III then the other is hydrogen.
More preferred R1 compositions of the invention comprise at least one compound of formula I wherein:
R1 is selected from the group consisting of C1 to C18 alkyl; C1 to C18 alkenyl; phenyl; and benzyl;
R2 is hydrogen or C1 to C4 alkyl; and wherein R1 and
R2 may form a carbocyclic ring by the bridging group of formula
-CH2(CR7R8)CH2-
wherein R7 and R8 are independently selected from hydrogen and C1 to C4 alkyl;
R3 is selected from C2 to C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group consisting of hydroxy and C1 to C9 alkoxy; C1 to C18 alkenyl; benzoyl; benzyl; benzoyl substituted with a substituent selected from C1 to C6 alkyl and C1 to C6 alkoxy; and C1 to C9 alkanoyl; R4 is C1 to C4 alkyl n is from 0 to 3
R5 and R6 are selected such that they comply with one of the possibilities selected from the group consisting of (i) R5 and R6 are independently selected from hydrogen and C1 to C4 alkyl; (ii) one of R5 and R6 is hydrogen and the other is a group of formula III
III
Figure imgf000011_0001
wherein R10, R11 and R12 are independently selected from the group consisting of hydrogen and C1 to C4 alkyl; and (iii) the group wherein R5 and R6 form a spiro carbocyclic ring by the group of formula Ila
( II a
Figure imgf000011_0002
wherein R10 and R11 are independently selected from the group consisting of hydrogen and C1 to C4 alkyl. In a particularly preferred group of compositions of the invention the compound of formula I is selected such that
R1 is selected from the group consisting of C1 to
C18 alkyl; C1 to C18 alkenyl; phenyl; and benzyl;
R2 is hydrogen or C1 to C4 alkyl; and wherein R1 and R2 may form a carbocyclic ring by the bridging group of formula
-CH2(CR7R8)CH2- wherein R7 and R8 are independently selected from hydrogen and C1 to C4 alkyl;
R3 is selected from C1 to C18 alkyl;
C2 to C18 alkenyl; benzoyl; benzyl; benzoyl substituted with a substituent selected from C1 to C6 alkyl and C1 to C6 alkoxy; and C3 to C9 alkanoyl;
R is C1 to C4 alkyl; n is from 0 to 3; and
R5 and R6 are independently selected from hydrogen and C1 to C4 alkyl.
Many of the compounds for use in preparing of compositions of the inventions are novel compounds .
According to a further embodiment of the invention there is therefore provided a compound of formula I
Figure imgf000012_0001
wherein:
R1 is selected from the group consisting of: C1 to C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group of hydroxy, amino, C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl, (C1 to C9 alkoxy)carbonyl, carbamoyl, (C1 to C6 alkyl)carbamoyl and phenyl; C2 to C18 alkenyl; C2 to C9 alkenyl substituted with a substituent selected from the group consisting of hydroxy, amino, C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl, carbamoyl, (C1 to C9 alkyl)carbamoyl, and phenyl; C2 to C18 alkynyl; phenyl; the groups phenyl and benzyl said groups being substituted in the benzene ring with a substituent is selected from the group of C1 to C12 alkyl, C1 to C12 alkoxy, C1 to C12 alkenyloxy, C1 to C12 alkylamino, N,N-di(C1 to C6 alkyl)amino, (C1 to C12 alkoxy)carbonyl and C1 to C12 alkanoyl; C5 to C7 cycloalkyl; C5 to C7 cycloalkenyl; the groups substituted C5 to C7 cycloalkyl and substituted C5 to C7 cycloalkenyl wherein the substituent is selected from the group of hydroxy, amino, C1 to C9 alkyl, C1 to C9 alkoxy, and C1 to C9 alkenyloxy; polymers of one or more of the monomers selected from ethylene glycol, propylene glycol, styrene and C2 to C4 alkenes, and derivatives of said polymers; and wherein R1 may optionally link together with R2 to form a carbocyclic ring by the bridging group of formula -(R7R8C)m- wherein m is 2 or 3 and R7 (which may be the same or different) and R8 (which may be the same or different) are independently selected from the group of hydrogen and C1 to C6 alkyl; R3 is selected from the group consisting of: C2 to C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group of amino, C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl, (C1 to C9 alkoxy)carbonyl, carbamoyl, (C1 to C6 alkyl)carbamoyl and phenyl; C2 to C18 alkenyl; C2 to C9 alkenyl substituted with a substituent selected from the group consisting of hydroxy, amino C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl, (C1 to C9 alkoxy)carbonyl, carbamoyl, (C1 to C9 alkyl) carbamoyl and phenyl; C2 to C18 alkynyl; phenyl; benzoyl; the groups phenyl, benzyl and benzoyl said groups being substituted in the benzene ring with a substituent selected from the group of hydroxy, amino, C1 to C12 alkyl, C2 to C12 alkenyl, C1 to C12 alkoxy, C2 to C12 alkenyloxy, C1 to C12 alkylamino, N,N-di-(C1 to C6 alkyl)amino, (C1 to C12 alkoxy)carbonyl, and C1 to C12 alkanoyl; C5 to C7 cycloalkyl; C5 to C7 cycloalkenyl; the groups substituted C5 to C7 cycloalkyl and substituted C5 to C7 cycloalkenyl wherein the substituent is selected from the group of hydroxy, amino, C1 to C9 alkyl, C1 to C9 alkoxy, and C1 to C9 alkenyloxy; C1 to C18 alkanoyl; C1 to C9 alkanoyl substituted with a substituent selected from the group of hydroxy, amino, C1 to C9 alkoxy and C2 to C9 alkenyloxy, C1 to C9 alkanoyl; carbomoyl, C1 to C6 alkyl)carbamoyl, (C1 to C9 alkoxy)carbonyl and phenyl; polymers of one or more monomers selected from ethylene glycol, propylene glycol, styrene and C2 to C4 alkenes, and derivatives of said polymers; and the group -OROROR9 wherein R (which may be the same or different) is a bivalent hydrocarbon radical of 2 to 6 (more preferably 2 to 4) carbon atoms and R9 is a hydrocarbon radical selected from C1 to C6 alkyl, C2 to C6 alkenyl, phenyl, benzyl, (C1 to C6 alkyl) phenyl and (C1 to C6 alkyl)benzyl (more preferably R9 is selected from C1 to C4 alkyl and C2 to C4 alkenyl); R2 is selected from the group consisting of hydrogen, C1 to C6 alkyl, and the group wherein R1 and R2 together form a bridging group of formula
-(CR7R8)m- wherein R7, R8 and m are as hereinbefore defined;
R4 is selected from the group consisting of C1 to C6 alkyl and C1 to C6 alkoxy; n is an integer selected from 0 to 4 inclusive; and R5 and R6 which may be the same or different are selected from hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy C1 to C10 alkanoyl, C1 to C10 alkanoyl substituted by carboxyl or (C1 to C6 alkoxy)carbonyl and wherein R7 and R8 may form a spiro-carbocylic ring by the bridging group of formula II
(CR10 R11) II
Figure imgf000015_0001
wherein q is 2 or 3 and R10 and R11 may be the same or different at each carbon unit of the bridge and are independently selected from hydrogen and C1 to
C8 alkyl; with the proviso that when R1 is methyl R3 is not selected from the group of benzyl, hydroxyethyl and methoxymethyl.
Where reference is made herein to a group comprising an alkyl, alkenyl or alkynyl moiety it will be understood that said moiety may be a straight or branched chain moiety, for example, the group C1 to C18 alkyl includes straight and branched chain alkyl of 1 to 18 carbon atoms and the group C1 to C9 alkoxy includes groups wherein the alkyl portion of the alkoxy group is straight or branched chain of from 1 to 9 carbon atoms. In compounds of formula I, as hereinbefore described the substituents R1 and/or R3 may be a polymer of one or more of the monomers selected from ethylene glycol, propylene glycol and C2 to C4 alkenes and derivatives thereof. Examples of the derivatives may include derivatives comprising at least one group of formula XI (a) or XI (b)
Figure imgf000016_0001
wherein R1, R2, R3, R4, R5, R6 and n are as hereinbefore defined. When the polymer is a polymer of ethylene glycol or propylene glycol examples of derivatives thereof may include ethers formed by a bond of the terminal oxygen with a radical selected from the group of C1 to C6 alkyl, phenyl, benzyl, and the groups phenyl and benzyl substituted in the benzene ring with C1 to C9 alkyl. Preferably the polymers contain in the range of from 3 to 18 monomeric units.
Preferably in the compounds of the invention of formula I R1 is selected from C1 to C18 alkyl; C2 to C9 alkyl substituted with a substituent selected from the group consisting of hydroxy, amino, C1 to C9 alkoxy, C1 to C9 alkanoyl and (C1 to C9 alkoxy)carbonyl; C1 to C18 alkenyl; cyclohexyl; phenyl; benzyl; the groups phenyl and benzyl said groups being substituted in the benzene ring with a substituent selected from the group of C1 to C9 alkyl, C2 to C9 alkenyl, C1 to C9 alkoxy, C1 to C9 alkanoyl and (C1 to C9 alkoxy)carbonyl; and wherein R1 may optionally link together with R2 by the a bridging group of formula -CH2(R7R8C)CH2- wherein R7 and R are independently selected from hydrogen and C1 to C6 alkyl; R3 is selected from C2 to C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group consisting of hydroxy, amino, C1 to C9 alkoxy and C1 to C9 alkanoyl; C2 to C1g alkenyl; cyclohexyl; phenyl; benzyl; benzoyl; the groups phenyl, benzyl and benzoyl said groups being substituted in the benzene ring with a substituent selected from the group of C1 to C9 alkyl, C2 to C9 alkenyl, C1 to C9 alkoxy, C1 to C9 alkanoyl and (C1 to C9 alkoxy)carbonyl; C3 to C18 alkanoyl; and C2 to C18 alkanoyl substituted with phenyl; R2 is selected from hydrogen and C1 to C6 alkyl; and wherein R 2 may link together with R1 to form a carbocyclic ring by the bridging group of formula -CH2(R7R8C)CH2- wherein R7 and R8 are independently selected from hydrogen and C1 to C6 alkyl;
R4 is C1 to C6 alkyl; n is from 0 to 4; and
R5 and R6 are independently selected from hydrogen; the group of formula III
Figure imgf000017_0001
wherein R10, R11 and R12 are independently selected fromC1 to C4 alkyl and hydrogen; and wherein R5 and R6 may form a spiro-carbocyclic ring by the bridging group of formula II (a)
II (a)
Figure imgf000018_0001
wherein R10 and R11 are independently selected from hydrogen and C1 to C4 alkyl. Preferably wherein one of R5 and R6 is the group of formula III then the other is hydrogen.
More preferably in compounds of the invention: R1 is selected from C1 to C18 alkyl; C1 to C6 alkyl substituted with a substituent selected from C1 to C6 alkanoyl and (C1 to C6 alkoxy)carbonyl; C1 to C18 alkenyl; phenyl; and benzyl;
R2 is selected from hydrogen and C1 to C4 alkyl and wherein R1 and R2 may form a carbocyclic ring by the bridging group of formula
-CH2(R7R8C)CH2-
wherein R7 and R8 are independently selected from hydrogen and C1 to C4 alkyl. R3 is selected from C2 to C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group consisting of hydroxy and C1 to C9 alkoxy; C1 to C18 alkenyl; benzoyl; benzyl; benzoyl substituted with a substituent selected from C1 to C6 alkyl and C1 to C6 alkoxy; and C3 to C9 alkanoyl; R4 is C1 to C4 alkyl; n is from 0 to 3; and
R5 and R6 are selected such that they comply with one of the possibilities selected from the group consisting of (i) R5 and R6 are independently selected from hydrogen and C1 to C4 alkyl; (ii) one of R5 and R6 is hydrogen and the other is a group of formula III
III
Figure imgf000019_0002
wherein R10, R11 and R12 are independently selected from hydrogen and C1 to C4 alkyl; and (iii) the group wherein R5 and R6 form a spiro carbocyclic ring by the diradical group of formula Ila
II a
Figure imgf000019_0001
wherein R10 to R11 are independently selected from hydrogen and C1 to C4 alkyl.
Even more preferably compound of the invention are compounds of formula I wherein:
R1 is C1 to C9 alkyl; R2 is selected from hydrogen and C1 to C4 alkyl; and wherein R1 and R2 may form a carbocyclic ring by the bridging group of formula
-CH2(CR8R9)CH2-
wherein R8 and R9 are methyl; R3 is selected from C2 to C9 alkyl, C2 to C9 alkenyl; C1 to C9 alkyl substituted with a substituent selected from hydroxy, phenyl and C1 to C6 alkoxy; benzoyl; benzoyl substituted with a substituent selected from the group consisting of C1 to C6 alkyl and C1 to C6 alkoxy, and C1 to C9 alkanoyl;
R4 is selected from C1 to C4 alkyl; n is from 0 to 3;
R5 and R6 are selected such that they comply with one of the possibilities selected from the group consisting of (i) R5 and R6 are independently selected from hydrogen and C1 to C4 alkyl; (ii) one of R5 and R6 is hydrogen and the other is a group of formula III
III -
Figure imgf000020_0002
wherein R10 and R11 are methyl and R12 is hydrogen or C1 to C4 alkyl; and (iii) the group wherein R5 and R6 form a spiro carbocyclic ring by the diradical group of formula II a
II a
Figure imgf000020_0001
wherein R10 and R11 are methyl. Preferably when one of R5 and R6 is not hydrogen or C1 to C4 alkyl then n is zero. In the most preferred compounds of the invention: R1 is seleted from the group consisting of methyl, ethyl, propyl and 4-methylbutyl; R2 is hydrogen or methyl; and wherein R1 and R2 may form a carbocyclic ring by the bridging group of formula:
-CH2(CR7R8)CH2-
wherein R7 and R8 are methyl;
R3 is selected from the group consisting of:C1 to C9 alkyl such as
propyl, butyl, 1-methylethyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, hexyl, 2-ethylhexyl, 1-methylpentyl, 1,1-dimethylbutyl, octyl, 1-methylheptyl and 3-methyl-2-butenyl; 2-phenylethyl; benzoyl, 3-methoxybenzoyl; 4-butylbenzoyl; propanoyl; benzyl;and cyclohexyl;
R4 is methyl; n is chosen from 0 to 3 and is conveniently zero.
R5 and R6 are selected such that they comply with one of the possibilities selected from the group consisting of (i) R5 and R6 are independently selected from hydrogen and methyl; (ii) one of R5 and R6 is hydrogen and the other is a group of formula III
III
Figure imgf000021_0001
wherein R10 and R11 are methyl and R12 is ethyl; and (iii) the group wherein R5 and R6 form a spiro carbocyclic ring by the diradical group of formula IIa. II a
Figure imgf000022_0001
wherein R10 and R11 are methyl.
One group of compounds of the invention which may be used in preparation of sunscreen compositions include compounds of formula la
Figure imgf000022_0002
wherein
R3, R4,R5and R6 are as hereinbefore defined in relation to compounds of the invention, R13 is C1 to
C4 alkyl and y is from 0 to 3.
Preferrred compounds of formula la include compounds of formula I (a) (i)
Figure imgf000022_0003
wherein R3, R4, R5, R6, R7, R8 and n are as hereinbefore defined.
Included in the more preferred compounds of the invention of formula I
Figure imgf000022_0004
are compounds where R5 and R6 are independently selected from hydrogen, C1 to C6 alkyl and C1 to C6 alkoxy, preferably from hydrogen and C1 to C6 alkyl; more preferably from hydrogen and C1 to C4 alkyl such as methyl; and R1, R2, R3, R4 and n are as hereinbefore defined.
For example, such compound include compounds wherein R1 is selected from the group consisting of methyl, ethyl, propyl, 3-methylbutyl; R2 is hydrogen; R3 is selected from the group consisting of propyl,
1-methylethyl, butyl, 3-methylbutyl, 2-ethylhexyl and 3-mehtyl-2-butenyl; n is 0; and R5 and R6 are hydrogen.
The compounds of formula 1(a) (i) include such compounds wherein R5 and R6 are hydrogen and R3 is as hereinbefore defined and n is 0, that is the compounds of formula 1(a) (ii)
Figure imgf000023_0001
wherein R7 and R8 are as hereinbefore defined.
When in the compounds of formula I (a) R5 and R6 comprise the groups of formula III or formula Ila it is preferred that R7 is identical with the group R10 and R5 is identical with the group R11. Specific examples of compounds embraced by the invention include.
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
The compounds of formula I may be prepared by a variety of methods and in a further aspect of the invention there is provided methods for the preparation of compounds of the invention of formula I.
The compounds may generally be derived via a suitable tetrahydropyridine compound of formula IV or via a pyridine derivative of formula V (wherein A are independently selected from hydrogen and R4).
Figure imgf000027_0002
IV
The preparation of the compound of formula I from the pyridine derivative of formula V may be carried out by reduction of the compound of formula V for example using hydrogen in the presence of a catalyst (such as palladivim on charcoal catalyst) to give a compound of the invention of formula I(c).
1(c)
Figure imgf000027_0001
The pyridine derivative of formula V may be prepared from the compound of formula VII (wherein A
4 are independently selected from hydrogen and R ) reaction thereof with the compound of formula VI
(wherein L is a leaving group).
_3 L
VI
Figure imgf000028_0001
VII
The preparation of a compound of formula I from the compound of formula IV may be carried out by reacting the compound of formula IV, preferably in the presence of a base, with a compound of formula VI wherein L is a leaving group.
The compound of formula IV having the specific formula IVa may be prepared by reduction of the pyridine of formula VII, for example using hydrogen in the presence of a catalyst such as palladium on charcoal.
Alternatively the compound of formula IV (having the specific formula IVb) may be prepared by chemical reduction of the compound of formula VIII
Figure imgf000028_0002
wherein A which may be the same or different is chosen from hydrogen or R4 as hereinbefore defined.
N=C-(CR5R6)CA2
Figure imgf000029_0001
VIII
(A is independently selected from hydrogen and R4). In compound of formula VI the leaving group
(L) may be chosen by those skilled in the art.
Examples of leaving groups include chloride, bromide, iodide, sulfate, nitrate, methylsulfate, ethylsulfate, tetrafluoroborate, hexafluorophosphate, hexafluoro- antiminate, methanesulfonate, fluorosulfonate, fluoromethanesulfonate and trifluoromethanesulfonate.
An alternative method of preparation of the compound of formula IV may involve reaction of the compound of formula XII with a compound of formula XIII in the presence of a base such as an amine to give the compound of formula XIV and hydrogenation of the compound of formula XIV to give the compound of formula IV(c) which may be converted as herein before described to a compound of the invention of formula I having the specific formula Kb). A preferred example of this alternative method is the reaction of the compound of Xlll with mesityl oxide to give the compound of formula IV which has the formula XV which may be utilised in providing compounds of formula I having & 4, 4, 6-trimethyl substitution in the tetrahydro pyridine ring, for example, the compound methyl 1-butyl-4,4,6-trimethyl-1, 4,5, 6-tetrahydro-3-pyridyl ketone.
Figure imgf000030_0001
(A is independently selected from hydrogen and R4) A similar scheme may be used for more direct preparation of the compound of formula I by reaction of the compound of formula XII with a compound of formula XVI followed by hydrogenation of the intermediate of formula XVII to give a compound of the invention of formula Kb).
Figure imgf000031_0002
XVI XVII
There is further provided a process for preparation of a compound of formula I (a) (iii)
I (a)(iii)
wherein R5 and R6 together from the spiro carbocyclic ring by the diradical group of formula II a
II a
Figure imgf000031_0003
or one of R5 and R6 is hydrogen and the other is the group of formula III
IX I 10 11 R12
Figure imgf000032_0002
and R3, R10, R11 and R12 are as hereinbefore defined; which process comprises reacting a compound of formula IX with formaldehyde
IX
Figure imgf000032_0001
in presence of an acid to give a compound of the invention of formula I (a) (iii) wherein R5 and R6 from said spiro carbocyclic ring of formula IIa; and optionally reacting the spiro carbocyclic moiety with a base of formula X.
12
X
, wherein Mis an alkali metal cation, to provide a compound of the invention of formula I (a) (iii).
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
TABLE 1b (Cont 'd)
b.
Figure imgf000036_0001
c. -C-CH2C(CH3)2 CH2CO2C2H5
In a further embodiment of the invention, there is provided a method of screening a surface from ultra-violet radiation, the method comprising applying to the surface a composition comprising a compound of formula I as hereinbefore described. The compositions of the present invention are particularly useful for protection of human skin against harmful effects of sunlight. Human skin is well known to be sensitive to sunlight containing radiation of wavelengths between about 270 nm and 400 nm.
The OV-B region of ultra violet radiation (290-320 nm) has long been known to cause damage to skin but more recently concern has been expressed over the effect of UV-A radiation (above 320 nm).
Compositions of the present invention may be prepared comprising one or more compounds of formula I and may provide screening in the UV-A region, the UV-B region or in both of these regions. Consequently, in one embodiment of the invention there is provided a method of protecting skin from ultra-violet radiation, the method comprising applying to the surface of the skin a composition as hereinbefore described. A specific example of a sunscreen formulation which may be used in preparation of compositions of the present invention includes the following Sunscreen lotion composition % w/w
Methyl para-hydroxy benzoate 0.25
Propyl para-hydroxy benzoate 0.10
Cetyl/Stearyl 2-Ethylhexonoate 2.00 "CARBOMER" 491 thickener (cross linked acrylic 0.45 acid polymer)
Phenyl trimethicone 1.00
Stearic Acid 3.00
Sodium Hydroxide 0.15 Phenoxyethanol 0.30
Isopropyl Isostearate 5.00 Antioxidant (BHA, BHT, ascorbates, tocopherols)0.08
Glyceryl Monostearate & PEG 100 Stearate 1.00
Fragrance 0.10 Sunscreen Compound 6.00
Disodium EDTA 0.05
Treated water 80.52
("CARBOMER" is a trade mark)
The invention is now illustrated by, but in o way limited to, the following examples.
Example 1
Methyl 1-(1-methylethyl)-1,4,5.6-tetrahydro-3- pyridyl ketone (1)
a) 3-acetyl-1,4,5,6-tetrahydropyridine was prepared by hydrogenation of 3-acetyl pyridine in the presence of palladium on carbon according to the method of Freifelder, J.Org.Chem. 29, 2895 (1964).
b) 3-acetyl-1,4,5,6-tetrahydropyridine (20.0 g, 0.16 mole) was added under nitrogen to a mixture of sodium hydride (5.75 g, 0.24 mole) and dry dimethylformamide (50 ml) stirring at 0°C and stirring was continued for 15 minutes. 2-Bromopropane (21.5 g, 0.175 mole) was then added dropwise over 15 min, stirring continued for a further hour at 0°C then overnight at room temperature. The reaction mixture was cautiously added to iced water (100 g) under nitrogen and extracted with diethyl ether (3 x 100 ml). The combined organic phase was extracted with water (150 ml), dried over magnesium sulphate, concentrated under reduced pressure to give methyl 1-(1-methylethyl)- 1,4,5,6-tetrahydro-3-pyridyl ketone (1). The product was distilled as a pale yellow oil (b.pt 97-98°C/0.5 mm Hg). Example 2
Methyl 1-propyl-1 , 4 , 5 , 6-tetrahydro-3-Pyridyl ketone (2)
a) Methyl 1-propyl-1 ,4 ,5, 6-tetrahydro-3-pyridyl ketone was prepared from 3-acetyl-1 , 4 , 5 , 6- tetrahydropyridine and 1-bromopropane according to the procedure of Part b) of Example 1. The product distilled as a pale yellow (b.pt98-100°C/0.5 mm Hg) .
Example 3
Methyl 1-(3-methylbutyl)-1,4,5,6-tetrahydro-3- pyridyl ketone (3)
Methyl 1-(3-methylbutyl)-1,4,5,6-tetrahydro-3- pyridyl ketone was prepared from 3-acetyl-414,5,6- tetrahydropyridine and 1-bromo-3-methylbutane according to the procedure of Part b) of Example 1. The product distilled as a pale yellow oil (b.pt. 103-106°C/0.1 mm Hg).
Example 4
Methyl 1-(3-methyl-2-butenyl)-1,4,5,6-tetrahydro-3- pyridyl ketone (4)
a) A mixture of 3-acetylpyridine (12.1 g, 0.1 mole) and 1-bromo-3-methyl-2-butene (22.3 g, 0.15 mole) was stirred at room temperature under nitrogen overnight. The mixture was diluted with diethyl ether (25 ml) and the cream coloured crystalline solid, 1-(3-methyl-2-butenyl)-3-acetyl pyridinium bromide, was filtered off under nitrogen. b) 1-(3-methyl-2-butenyl)-3-acetyl-pyridinium bromide (27.0 g, 0.1 mole) and triethylamine (10.1 g, 0.1 mole) in ethyl alcohol (50 ml) over 5% palladium on carbon (5 g) was hydrogenated at room temperature and pressure until two molar equivalents of hydrogen was taken up. The catalyst was removed by f iltration and the filtrate concentrated at reduced pressure. The semi-solid residue was diluted with diethyl ether (75 ml) , the solid removed by filtration and the filtrate concentrated under reduced pressure to leave a pale oil which solidified on standing. Recrystallisation from ethanol/water gave the product, methyl 1-( 3-methylbutenyl)-1,4,5,6- tetrahydro-3-pyridyl ketone (4) as a pale yellow crystalline solid m.p. 76-78°C.
Example 5
Methyl 1-(2-ethylhexyl)-1,4,5,6-tetrahydro-3-pyridyl ketone (5)
a) 3-acetyl-1,4,5,6-tetrahydropyridine (20.0 g, 0.16 mole) was added under nitrogen to a mixture of sodium hydride (5.76 g, 0.24 mole) and dry tetrahydrofuran (50 ml) stirring at room temperature. After one hour, l-bromo-2-ethyl hexane (33.8 g, 0.175 mole) was added dropwise over 15 minutes and the mixture stirred overnight at room temperature. The reaction mixture was cautiously added to iced water (100 g) under nitrogen and extracted with diethyl ether (3 x 100 ml). The combined organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residue distilled to give methyl 1- ( 2-ethylhexyl ) - 1, 4, 5, 6- tetrahydro-3-pyridyl ketone (5 ) as a pale yellow oil (b.pt 140-142°C/0. 1 mm Hg) .
Example 6
Methyl 1-(2-phenylethyl)-1,4,5,6,-tetrahydro-3- pyridyl ketone (6)
a) A mixture of 3-acetyl pyridine (12.1 g, 0.1 mole) and (2-bromoethyl)benzene (37.0 g, 0.2 mole) was heated at 100°C under nitrogen for four hours. After cooling, the mixture was diluted with diethyl ether (25 ml) and the pale brown crystalline solid, 1-(2-phenyl ethyl)-3-acetyl-pyridinium bromide, was filtered off under nitrogen.
b) A solution of 1-(2-phenylethyl)-3-acetyl- pyridinium bromide (30.6 g, 0.1 mole) and triethylamine (10.1 g, 0.1 mole) in ethyl alcohol (50 mole) over 5% palladium on carbon (5 g) was hydrogenated at room temperature and pressure. Upon cessation of hydrogen uptake, the catalyst was filtered and the filtrate concentrated at reduced pressure. The semi-solid filtered and the filtrate concentrated under reduced pressure to leave a pale brown oil, methyl 1-(2-phenyl ethyl)-1,4,5,6-tetrahydro-3-pyridyl ketone (6). Example 7
Methyl 1-benzoyl-l,4,5,6-tetrahydro-3-pyridyl ketone (7)
a) Methyl 1-benzoyl-1,4,5,6-tetrahydro-3-pyridyl ketone was prepared from 3-acetyl-1,4,5,6- tetrahydropyridine and benzoyl chloride according to the procedure of Part b) of Example 1. The product was recrystallised from ethanol/water m.pt. 93-95°C.
Example 8 and Example 9
Methyl 1-(3-methylbutyl)-2-methyl-1,4,5,6-tetrahydro -3-pyridyl ketone (9)
Example 8
a) 4,4-Diacetylbutyronitrile was prepared by addition of acrylonitrile to the sodium salt of acetyl acetone according to the procedure of Johnson et al, J.Chem.Soc (C), 1969, 176.
b) A solution of 4,4-diacetylbutyronitrile (15.3g, 0.1 mole) in ethyl alcohol (50 ml) over Raney nickel (2g) was hydrogenated at room temperature and three atmospheres pressure. After hydrogen uptake had ceased, the catalyst was filtered off and the filtrate concentrated under reduced pressure to give 3-acetyl-2-methyl-1,4,5,6-tetrahydro- pyridine. Example 9
Methyl
1-(3-methylbutyl)-2-methyl-1,4,5,6-tetrahydro-3-pyr- idyl ketone was prepared from 3-acetyl-2-methyl, 1,4,5,6-tetrahydro- pyridine and 1-bromo-3- methylbutene according to the procedure of Part b) of Example 1.
Example 10
Ethyl 1-butyl-l,4,5,6-tetrahydro-3-pyridyl ketone (10)
a) A mixture of ethyl nicotinate (15.1g, 0.1 mole), ethyl propionate (15.3g, 0.15 mole) and sodium ethoxide (10.2g, 0.15 mole) was stirred and heated under nitrogen at 100°C for five hours. After cooling, the mixture was diluted with water (150 ml) extracted with diethyl ether (50 ml) and the aqueous layer made acidic to pH 1 with concentrated hydrochloric acid (50 ml). The aqueous layer was heated at 90°C for two hours, cooled, made alkaline with solid potassium carbonate and extracted with diethyl ether (3 x 75 ml). The dried (magnesium sulphate) organic layer was concentrated and distilled to give ethyl 3-pyridyl ketone (b.pt 97-99°/14mm Hg).
b) Ethyl 3-pyridyl ketone was reacted with 1- bromobutane according to the procedure of Para a) of Example 6 to give 1-butyl(3- pyridinium bromide as a tan coloured crystalline solid. c) 1-Butyl-3-propionyl pyridinium bromide was hydrogenated according to the procedure described in Para, b) at Example B to -give ethyl 1-butyl-1,4,5,6-tetrahydro-3-pyridyl ketone (10). The product was distilled as a pale yellow oil (b.pt. 108-109°C/0.1 mm Hg).
Example 11
Ethyl 1-(3-methylbutyl)-1,4,5,6-tetrahydro-3-pyridyl ketone (11)
a) Ethyl 3-pyridyl ketone was reacted with 1-bromo-3-methylbutane according to the procedure of Parb a) of Example 6 to give 1-(3-methylbutyl)-3-propionyl pyridinium bromide as a pale brown crystalline solid.
b) 1-(3-Methylbutyl)-3-propionyl pyridium bromide was hydrogenated according to the procedure of Parb b) of Example 6 to give ethyl 1-(-3-methylbutyl-1,4,5,6-tetrahydro- 3-pyridyl ketone. The product was distilled as a pale yellow oil (b.pt. 111-112°C/0.02 mm Hg). Example 12
Propyl 1-propyl-1,4,5,6-tetrahydro-3-pyridyl ketone (12)
a) A mixture of ethyl nicotinate (15.1g, 0.1 mole), ethyl butyrate (17.4g, 0.15 mole) and sodium ethoxide (10.2g, 0.15 mole) was stirred and heated under nitrogen at 100°C for five hours. After cooling, the mixture was diluted with water (150 ml), extracted with diethyl ether (50 ml) and the aqueous layer made acidic to pHl with concentrated hydrochloric acid (50 ml). The aqueous layer was heated at 90°C for 2 hours, cooled, and made alkaline with solid potassium carbonate and extracted with diethyl ether (3 x 75 ml). The dried (magnesium sulphate) organic layer was concentrated and distilled to give propyl 3-pyridyl ketone (b.pt.H8-120°C/14 mm Hg).
b) Propyl 3-pyridyl ketone was reacted with 1- bromo-2-propene according to the procedure of
Part a) of Example 4 to give 1-(2-propenyl)- 3-butyryl pyridium bromide as a cream coloured crystalline solid.
c) 1-(2-Propenyl)-3-butyryl pyridinium bromide was hydrogenated according to the procedure described in Part b) of Example 6 to give propyl 1-propyl-1,4,5,6-tetrahydro-3-pyridyl ketone. The product was distilled as a pale yellow oil (b.pt 150-153ºC/0.3 mm Hg) Example 13
Propyl 1-butyl-1,4,5,6-tetrahydro-3-pyridyl ketone (13)
a) Propyl 3-pyridyl ketone was reacted with 1- bromobutane according to the procedure of
Part a) of Example 6 to give 1-butyl-3- butyryl pyridinium bromide as a tan coloured crystalline solid.
b) 1-Butyl-3-butyryl pyridinium bromide was hydrogenated according to the procedure described in Part b) of Example 6 to give propyl 1-butyl-1-4,5,6-tetrahydro-3-pyridyl ketone (13). The product was distilled as a pale yellow oil (b.pt. 120-124°C/0.02 mm Hg).
Example 14
Propyl 1-(3-methylbutyl)-1,4,5,6-tetrahydro-3- pyridyl ketone(14)
a) Propyl 3-pyridyl ketone was reacted with 1-chloro-3-methyl-2-butene according to the procedure of Part a) of Example 4 to give
1-(3-methyl-2-butenyl)-3-butyryl pyridinium chloride as a cream coloured crystalline solid.
b) 1-(3-Methyl-2-butenyl)-3-butyryl pyridinium chloride was hydrogenated according to the procedure described in Part b) of Example 6 to give propyl 1-(3-methylbutyl)-1,4,5, 6- tetrahydro-3-pyridyl ketone (14). The product was distilled as a pale yellow oil (b.pt. 126-129°C/0.02 mm Hg) .
Example 15
4-Methylpentanyl 1-propyl-1,4,5,6-tetrahydro-3- pyridyl ketone(15)
a) A solution of 3-cyanopyridine (26.0g, 0.25 mole) in dry diethyl ether (200 ml) was added dropwise over the hour to the Grignard reagent prepared from 1-bromo-3-methyl butane (40.7 g, 0.27 mole) and magensium (6.8g, 0.26 mole) in dry diethyl ether (50 ml) under nitrogen. The mixture was heated at 35°C for eight hours, cooled to room temperature, and diluted with cold saturated aqueous ammonium chloride solution(200 ml) followed by concentrated hydrochloric acid (50 ml). The mixture was stirred for five hours, the ether layer separated, and the aqeuous layer boiled for two hours. The aqueous layer was neutralised to pH9 with aqueous sodium hydroxide solution and extracted with diethyl ether (3 x 100 ml). The organic phase was dried (magnesium sulphate), concentrated under reduced pressure and distilled to give 3-methylbutyl 3-pyridyl ketone.
b) 3-Methylbutyl 3-pyridyl ketone was reacted with 1-bromo-2-propene according to the procedure of Part a) of Example 4 to give 1-(2-propenyl)-3-(4-methyl)valeryl pyridinium bromide as a tan coloured crystalline solid. c) 1-(2-Propenyl)-3-(4-methyl)valeryl pyridinium bromide was hydr ogenated according to the procedure of Part b) of Example 6 to give 4- methylpentanyl 1-propyl-1,4,5,6-tetrahydro- 3-pyridyl ketone (15) as a yellow oil.
Example 16
Phenyl 1-propyl-1,4,5,6-tetrahydro-3-pyridyl ketone (16)
a) 3-Benzoyl pyridine was reacted with 1-bromo-2-propene according to the procedure of Part a) of Example 4 to give 1-(2-propenyl)-3-benzeyl pyridinium bromide as a tan coloured crystalline solid.
b) 1-(2-Propenyl)-3-benzoyl pyridinium bromide was hydrogenated according to the procedure of Part b) of Example 6 to give phenyl 1- propyl-1,4,5,6-tetrahydro-3-pyridyl ketone (10) as a yellow oil.
Example 17
7,7-Dimethyl-1,2,3,4,7,8-hexahydro-1-propyl-quinolin -5(6H)-one(17)
a) 7,7-Dimethyl-1,2,3,4,7,8-hexahydro-quinolin-5 (6H)-one [prepared by the method of Grob and Kiefer, Helv. Chim Acta., 48 799, (1964)] was reacted with 1-bromopropane according to the procedure of Part (b) of Example 1 to give 7,7-dimethyl-1,2,3,4,7, 8-hexahydro- 1-propyl-quinolin-5(6H)-one (17) as an oil. Example 18
7,7-Dimethyl-1,2,3,4,7,8-hexahydro-1-(3-methylbutyl) -quinoline-5(6H)-one(18)
a ) 7,7-Dimethyl-1,2,3,4,7,8-hexahydro-quinolin- 5(6H)-one was reacted with 1-bromo-3-methyl- butane according to the procedures of Part b) of Example 1 to give 7,7-dimethyl-1,2,3,4,7, 8-hexahydro-1-(3-methylbutyl)-quinolin-5(6H)- one (18) as a pale yellow oil.
Example 19
7-7-Dimethyl-1,2,3,4,7,8-hexahydro-1-benzoyl- quinolln-5(6H)-one(19)
a) 7,7 Dimethyl-1,2,3,4,7,8-hexahydro-quinolin- 5(6H)-one was reacted with benzoyl chloride according to the procedure of Part b) of
Example 1 to give 7,7-dimethyl-1,2,3,4,7,8- hexahydro-1-benzoyl-quinolin-5(6H)-one(19) as a yellow solid.
Example 20 7,7-Dimethyl-1,2,3,4,7,8-hexahydro-1-(3-methoxybenzoyl)-quinolin-5(6H)-one(20)
a) 7,7-Dimethyl-1,2,3,4,7,8-hexahydro-quinolin- 5(6H)-one was reacted with 3-methoxybenzoyl chloride according to the procedure of Part b) of Example 1 to give 7,7-dimethyl-l,2,3,4, 7,8-hexahydro-1-(3-methoxybenzoyl)-quinolin- 5(6H)-one (20) as a pale yellow solid. Example 21
7,7-Dimethyl-1,2.3,4,7,8-hexahydro-1-(4-methoxybenzoyl)-quinoline-5(6H)-one(21)
a) 7,7-Dimethyl-1,2,3,4,7,8-hexahydro-quinoline- 5(6H)-one was reacted with 4-methoxybenzoyl chloride according to the procedure of Part b) of Example 1 to give 7,7-dimethyl-1,2,3,4, 7,8-hexahydro-1-(4-methoxybenzoyl)-quinoline- 5(6H)-one(21) as a yellow waxy solid.
Example 22
7,7-Dimethyl-1,2,3,4.7,8-hexahydro-1-(4-butyl- benzoyl)-quinolin-5(6H)-one(22)
a) 7,7-Dimethyl-1,2,3,4,7,8-hexahydro-quinoline -5(6H)-one was reacted with 4-butylbenzoyl chloride according to the procedure of Part b) of Example 1 to give 7,7-dimethyl-1,2,3,4, 7,8-hexahydro-1-(4-butylbenzoyl)-quinoline- 5(6H)-one(22) as a yellow solid.
Example 23
Preparation of 1,2,3,4,7,8 -hexahydro-1-hexyl-4', 4', 7, 7-tetramethylquinoline-3-spirocyclohexane -2', 5(6H)_ c'-trione (23)
a) A solution of 5,5-dimethyl-3-hexylamino cyclohex-2-enone (26.76 g;0.12 mole), aqueous formaldehyde (37%w/w; 9ml) and 2N hydrochloric acid (40 ml) was stirred at room temperature for 24h. The reaction was chilled on ice and made basic with 4N NH.OH. The resulting solid was collected by filtration, washed with water (3 x 100 ml) and dried in vacuo to give 19.2g (85.3%) of 1,2,3,4,7,8-hexahydro-1-hexyl-4',4',7,7- tetramethylquinoline-3-spirocyclohexane-2', 5(6H),6'-trione, m.p. 111.1 - 113.0°C.
max 314.0 mm ( = 27750)
Example 24
The reaction solution of Example 23 consisting of 5,5-dimethyl-3-hexylaminocyclohex-2-enone (26.76g; 0.12 mole), aqueous formaldehyde (37% w/w; 9 ml) and 2N hydrochloric acid (40 ml) was refluxed for 5 h. The reaction mixture was chilled on ice, made basic with 2N NH.OH, extracted into chloroform (3 x 100 ml) and dried over MgSO4. Evaporation of the chloroform and crystallisation of the residue from benzene/light petroleum gave 20.6g (91.6%) of 1,2,3,4,7,8-hexahydro-1- hexyl-4',4',7,7- tetramethylquinoline-3- spirocyclohexane-2', 5(6H),6'-trione, m.p. 111.1 - 113.0°C. Example 24
PMR (300 MHz;CDCl3
Figure imgf000052_0001
- ( ) 1 " 6"
Figure imgf000052_0002
Example 25 -35
Preparation of 1 -substituted-1,2,3,4,7 ,8-hexahydro-
4',4',7,7-tetramethylguinoline-3-spirocyclohexane-
2',5(6H),5 '-trione derivatives
The compound derivatives provided in Example 25 - 35 of the invention were prepared by the general method described in Example 23 or Example 24 and are listed in Table I where the R3 group is defined as the 1-substituent. TABLE 1
1-substituted (R3)-1,2,3,4,7,8-hexahvdro-4' ,4',7,7- tetramethylguinoline-3-spirocyclohexane-2',5(6h),6'- trione derivatives
Figure imgf000053_0001
Figure imgf000053_0002
boiling point (ºC/Torr). Example 36
Preparation of ethyl 3,3-dimethyl-5-(1,2,3,4,5,6,7, 8-octahydro-1-cyclohexyl-7,7-dimethylguinolin-3-yl -5-oxopentanoate(36)
The compound of Example 36 was prepared by a reverse Dieckmann reaction by the general equation (R3 = cyclohexyl):
Figure imgf000054_0001
1,2,3,4,7,8-Hexahydro-1-cyclohexyl-4'4 ,7,7- tetramethylquinoline-3-spirocyclohexane-2', 5(6H) 6'-trione (Example 25;6.6g; 0.0175 mole) was added to ethanolic sodium hydroxide [from sodium(0.9g)]and ethanol (80 ml)]. The mixture was refluxed for 2h and the ethanol evaporated in vacuo. The residue was treated with ice-cold water (100 ml) and the product extracted into chloroform (3 x 50 ml). The chloroform layer was dried over MgSO4 and evaporated to give the crude ester (3.9g; 54.0% as a pale yellow solid. The product was recrystalised from n-hexane/benzene to give pure ethyl 3,3-dimethyl-5- (1,2,3,4,5,6,7,8-octahydro-1-cyclohexyl-7,7- dimethylquinoline-3-yl)-5-oxopentanoate, m.p. 44-46ºC. max 318.6 mm, = 25,900 Example 37
The compounds of Examples 1 to 24 inclusive were characterised by, and can be identified by their 'H nuclear magnetic resonance spectra. The 'H nuclear magnetic resonance spectra for the compounds of Examples 1 to 23 are recorded in Table 2 below Table 2. UV s ectra 'H N.M.R.
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Example 38
1-[1-3-methylbutyl)-1,4,5,6-tetrahydro-3-pyridyl] pentan-2,5-dione (38)
1-[1-(3-methylbutyl)-1,4,5,6-tetrahydro-3-pyridyl] pentan-2,5-dione can be prepared from 1-(3-pyridyl) pentan-2,5-dione [obtained by the method of Steller and Bchreckenburg Chem.Ber., 1078, 2453 (1974)] according to the procedure of Example 14 parts (a) and (b). Example 39
Sunscreen compositions were prepared using the components shown in table 2.
Part Material % w/w
A Water 69.5
B Polypropylene glycol
Meristyl Ether 20.0
Glyceryl Stearate 5.0
Oleth 10 surfactant 5.0
Effective component 0.5
BHT antioxidant ) 0.02/0.2
Sodium thiosulphate )
Separate emulsion formulations were prepared using a mixture of parts A and B for each of compounds No. 3, 5, 13 and 18 as the effective component and the pH was adjusted to 7 by dropwise addition of 1 M NaOH.
Further compositions were prepared using a mixture of part A, B and C for each of compounds 3, 5, 13 and 18 as the effective component.

Claims

1. A sunscreen composition comprising as an effective component thereof at least one compound of formula I.
Figure imgf000062_0001
whereins R5 is selected from the group consisting of. C1 to C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group consisting of hydroxy, amino, C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl, (C1 to C9 alkoxy) carbonyl, carbamoyl, (C1 to C6 alkyl)carbamoyl and phenyl; C2 to C18 alkenyl; C2 to C9 alkenyl substituted with a substituent selected from the group consisting of hydroxy, amino, C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl, carbamoyl, (C1 to C6 alkyl)carbamoyl, and phenyl; phenyl; the groups phenyl and benzyl said groups being substituted in the benzene ring with a substituent is selected from the group of C1 to C12 alkyl, C1 to C12 alkoxy, C1 to C12 alkenyloxy, C1 to C12 alkylamino, N,N-di(C1to C9 alkyl)amino, (C1 to C12 alkoxy)carbonyl and C1 to C12 alkanoyl; C5 to C7 cycloalkyli C5 to C7 cycloalkenyl; the groups substituted C5 to C7 cycloalkyl and substituted C5 to C7 cycloalkenyl wherein the substituent is selected from the group consisting of hydroxy, amino, C1 to C9 alkyl, C1 to C9 alkoxy. and C1 to C9 alkenyloxy; polymers of one or more of the monomers selected from ethylene glycol, propylene glycol, styrene and C2 to C4 alkenes, and derivatives of said polymers; and wherein R1 and R2 may form a carbocyclic ring by the bridging group of formula -(R7R8C)m- wherein m is 2 or 3 and R7 (which may be the same or different) and R8 (which may be the same or different) are independently selected from the group of hydrogen and C1 to C6 alkyl;
R3 is selected from the group consisting of: C1 to C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group of amino, C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl,
(C1 to C9 alkoxy)carbonyl, carbamoyl, (C1 to C6 alkyl)carbamoyl and phenyl; C2 to C18 alkenyl; C2 to C9 alkenyl substituted with a substituent selected from the group consisting of hydroxy, amino C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl (C1 to C9 alkoxy)carbonyl, carbamoyl, (C1 to C9 alkyl) carbamoyl and phenyl; phenyl; benzoyl; the groups phenyl, benzyl and benzoyl said groups being substituted in the benzene ring with a substituent selected from the group consisting of hydroxy, amino, C1 to C12 alkyl, C2 to C12 alkenyl, C1 to C12 alkoxy, C2 to C12 alkenyloxy, C1 to C12 alkylamino,
N,N-di(C1 to C9 alkyl)amino, (C1 to C12 alkoxy)carbonyl and C1 to C12 alkanoyl; C5 to C7 cycloalkyl; C5 to C7 cycloalkenyl; the groups substituted C4 to C7 cycloalkyl and substiuted C4 to
C7 cycloalkenyl wherein the substituent is selected from the group of hydroxy, amino, C1 to C9 alkyl, C1 to C9 alkoxy, and C2 to C9 alkenyloxy; C1 to C18 alkanoyl; C2 to C9 alkanoyl substituted with a substituent selected from the group of hydroxy, amino, C1 to C9 alkoxy and C2 to C9 alkenyloxy, C1 to C9 alkanoyl; carbamoyl, (C1 to C6 alkyl)carbamoyl, (C1 to C9 alkoxy)carbonyl and phenyli polymers of one or more monomers selected from ethylene glycol, propylene glycol styrene and C2 to C4 alkenes, and derivatives of said polymers; and the group -OROROR9 wherein R (which may be the same or different) is a bivalent hydrocarbon radical of 2 to 6 carbon atoms and R9 is a hydrocarbon radical selected from C1 to C6 alkyl, C2 to C6 alkenyl, phenyl, benzyl, (C1 to C6 alkyl) phenyl and
(C1 to C6 alkyl)benzyl; R2 is selected from the group consisting of hydrogen, C1 to C6 alkyl, and the group wherein R1 and R2 form a carbocyclic ring by the bridging group of formula -(CR7R8)m- wherein R7, R8 and m are as hereinbefore defined; R4 is selected from the group consisting of C1 to C6 alkyl and C1 to 66 alkoxy; n is an integer selected from 0 to 4 inclusive; and R5 and R6 which may be the same or different are selected from hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy C1 to C10 alkanyl, C1 to C10 substituted by carboxyl or (C1 to C10 alkoxy) carbonyl and wherein R5 and R6 may form a spiro-carbocyclic ring by the bridging group of formula II
(CR10 R11)q II
wherein:
Figure imgf000064_0001
q is 2 or 3 and R10 and R11 may be the same or different at each carbon unit of the bridge and are independently selected from hydrogen and C1 to C8 alkyl.
2. A sunscreen composition according to claim 1 wherein in the compound of formula I: R1 is selected from the group consisting of: C1 to
C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group consisting of, hydroxy, amino, C1 to C9 alkoxy C1 to C9 alkanoyl and (C1 to C9 alkoxy)carbonyl; C1 to C18 alkenyl; cyclohexyl; phenyl; benzyl; the groups phenyl and benzyl said groups being substituted in the benzene ring with a substituent selected from the group of C1 to C9 alkyl, C2 to C9 alkenyl, C1 to C9 alkoxy, C1 to C9 alkylamino, N,N-di(C1 to C6 alkyl)amino, C1 to C9 alkanoyl and (C1 to C9 alkoxy)carbonyl; and wherein R1 and R2 may form a carbocyclic ring by the bridging group of formula -CH2(R7R8C)CH2- wherein R7 and R8 are independently selected from hydrogen and
C1 to C6 alkyl; R3 is selected from C1 to C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group consisting of hydroxy, amino, C1 to C9 alkoxy and C1 to C9 alkanoyl; C2 to C18 alkenyl; cyclohexyl; phenyl; benzyl; benzoyl; the groups phenyl, benzyl and benzoyl said groups being substituted in the benzene ring with a substituent selected from the group consisting of C1 to C9 alkyl, C2 to C9 alkenyl, C1 to C9 alkoxy, C1 to C9 alkylamino, N,N-di(C1 to C6 alkyl)amino, C1 to Cg alkanoyl and (C1 to C9 alkoxy)carbonyl; C1 to C18 alkanoyl; and C2 to C9 alkanoyl substituted with phenyl; R2 is selected from hydrogen and C1 to C6 alkyl; and wherein R2 and R1 may form a carbocyclic ring by the bridging group of formula -CH2(R7R8C)CH2- wherein R7 and R8 are independently selected from hydrogen and C1 to C6 alkyl;
R4 is C1 to C6 alkyl; and n is from 0 to 4;
R5 and R6 are independently selected from hydrogen; group of formula III
(CR10 R11) III
Figure imgf000066_0002
wherein R10 and R11 are independently selected from C1 to C4 alkyl and hydrogen; and R12 is selected from hydrogen and C1 to C6 alkyl, and wherein R5 and R6 may form a spiro-carbocyclic ring by the bridging group of formula Ila
II a
Figure imgf000066_0001
wherein R10 and R11 have independently selected from hydrogen and C1 to C4 alkyl.
3. A composition according to claim 1 or claim 2 wherein:
R1 is selected from the group consisting of C1 to
C18 alkyl; C1 to C18 alkenyl; phenyl; and benzyl;
R2 is hydrogen or C1 to C4 alkyl; and wherein R1 and R2 may form a carbocyclic ring by the bridging group of formula
-CH2(CR7R8)CH2-
wherein R7 and R8 are independently selected from hydrogen and C1 to C4 alkyl;
R3 is selected from C1 to C18 alkyl; C2 to C18 alkenyl; benzoyl; benzyl; benzoyl substituted with a substituent selected from C1 to C9 alkyl and C1 to C6 alkoxy; and C3 to C9 alkanoyl;
R4 is C1 to C4 alkyl;
n is from 0 to 3; and
R5 and R6 are independently selected from hydrogen and C1 to C4 alkyl.
4. A compound of formula I
Figure imgf000067_0001
whereint R1 is selected from the group consisting of: C1 to
C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group consisting of hydroxy, amino, C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl, (C1 to C9 alkoxy) carbonyl, carbamoyl, (C1 to C6 alkyl)carbamoyl and phenyl; C2 to C18 alkenyl; C2 to C9 alkenyl substituted with a substituent selected from the group consisting of hydroxy, amino, C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl, carbamoyl, (C1 to C9 alkyl)carbamoyl, and phenyl; C2 to C18 alkynyl; phenyl; the groups phenyl and benzyl said groups being substituted in the benzene ring with a substituent is selected from the group of C1 to C12 alkyl, C1 to C12 alkoxy, C2 to C12 alkenyloxy, C1 to
C12 alkylamino, N,N-di(C1 to C9 alkyl)amino, (C1 to C12 alkoxy)carbonyl and C1 to C12 alkanoyl; C5 to C7 cycloalkyl; C5 to C7 cycloalkenyl; the groups substituted C5 to C7 cycloalkyl and substituted C5 to C7 cycloalkenyl wherein the substituent is selected from the group consisting of hydroxy, amino, C1 to C9 alkyl, C1 to C9 alkoxy, and C1 to C9 alkenyloxy; polymers of one or more of the monomers selected from ethylene glycol, propylene glycol, styrene and C2 to C4 alkenes, and derivatives of said polymers; and wherein R1 and R2 may form a carbocyclic ring by the bridging group of formula
-(R7R8C)m- wherein m is 2 or 3 and R7 (which may be the same or different) and R8 (which may be the same or different) are independently selected from the group of hydrogen and C1 to C6 alkyl; R3 is selected from the group consisting of: C2 to
C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group consisting of amino, C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl, (C1 to C9 alkoxy)carbonyl, carbamoyl,
(C1 to C9 alkyl)carbamoyl and phenyl; C2 to C18 alkenyl; C2 to C9 alkenyl substituted with a substituent selected from the group consisting of hydroxy, amino C1 to C9 alkoxy, C2 to C9 alkenyloxy,
C1 to C9 alkanoyl, (C1 to Cg alkoxy)carbonyl, carbamoyl, (C1 to C9 alkyl) carbamoyl and phenyl; C2 to C18 alkynyl; phenyl, benzoyl; the groups phenyl, benzyl and benzoyl said groups being substituted in the benzene ring with a substituent selected from the group consisting of hydroxy, amino, C1 to C12 alkyl, C2 to C12 alkenyl, C1 to C12 alkoxy, C2 to
C12 alkenyloxy, C1 to C12 alkylamino, N,N-di(C1 to C6 alkyl)amino, (C1 to C12 alkoxy)carbonyl, and C1 to C12 alkanoyl; C5 to C7 cycloalkyl; C5 to C7 cycloalkenyl; the groups substituted C5 to C7 cycloalkyl and substituted C5 to C7 cycloalkenyl wherein the substituent is selected from the groups of hydroxy, amino, C1 to C9 alkyl, C1 to C9 alkoxy, and C1 to C9 alkenyloxy; C1 to C18 alkanoyl; C2 to C9 alkanoyl substituted with a substituent selected from the group consisting of hydroxy, amino, C1 to C9 alkoxy, C2 to C9 alkenyloxy, C1 to C9 alkanoyl, carbamoyl, C1 to C6 alkyl)carbamoyl, (C1 to C9 alkoxy)carbonyl and phenyl; polymers of one or more monomers selected from ethylene glycol, propylene glycol, styrene and C2 to C4 alkenes, and derivatives of said polymers; and the group -OROROR9 wherein R (which may be the same of different) are bivalent hydrocarbon radicals of 2 to 6 carbon atoms and R9 is a hydrocarbon radical selected from C1 to C6 alkyl, C2 to C9 alkenyl phenyl, benzyl, (C1 to C6 alkyl) phenyl and (C1 to C6 alkyl)benzyl;
R2 is selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, and the group wherein R1 and R2 may form a carbocyclic ring by the bridging group of formula (CH7R8)m- wherein R7, R8 and m are as hereinabove defined.
R4 is selected from the group consisting of C1 to C6 alkyl and C1 to C6 alkoxy; n is an integer selected from 0 to 4 inclusive; R5 and R6 which may be the same or different are selected from hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, C1 to C10 alkanoyl, C1 to C10 alkanoyl substituted by carboxyl or (C1 to C6 alkoxy) carbonyl and wherein R5 and R6 may form a spiro-carbocyclic ring by the bridging group of formula II.
C (CR10 R11)q II
Figure imgf000070_0001
q is 2 or 3 and R10 and R11 may be the same or different at each carbon unit of the bridge and are independently selected from hydrogen and C1 to C8 alkyl; with the priviso that when R1 is methyl then R3 is not selected from the group of hydroxyethyl, methoxymethyl and benzyl.
5. A compound according to claim 4 whereint R1 is selected from C1 to C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group consisting of hydroxy, amino, C1 to C9 alkoxy,
C1 to C9 alkanoyl and (C1 to C9 alkoxy)carbonyl; C1 to C18 alkenyl; cyclohexyl; phenyl; benzyl; the groups phenyl and benzyl said groups being substituted in the benzene ring with a substituent selected from the group of C1 to C9 alkyl, C2 to C9 alkenyl, C1 to C9 alkoxy, C1 to C9 alkanoyl and (C1 to C9 alkoxy) carbonyl; and wherein R1 and R2 may form a carbocyclic ring by the bridging group of formula -CH2(R7R8C)CH2- wherein R7 and R8 are independently selected from hydrogen and C1 to C6 alkyl;
R3 is selected from C2 to C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group consisting of hydroxy, amino, C1 to C9 alkoxy and C1 to C9 alkanoyl; C2 to C18 alkenyl; cyclohexyl; phenyl; benzyl; benzoyl; the groups phenyl, benzyl and benzoyl said groups being substituted in the benzene ring with a substituent selected from the group of C1 to C9 alkyl, C2 to C9 alkenyl, C1 to C9 alkoxy, C1 to C9 alkanoyl and (C1 to C9 alkoxy)carbonyl; C3 to C18 alkanoyl; and C2 to C9 alkanoyl substituted with phenyl;
R2 is selected from hydrogen; C1 and C6 alkyl; and wherein R1 and R2 may form a carbocyclic ring by the bridging group of formula -CH2(R7R8C)CH2- wherein R7 and R8 are independently selected from hydrogen and
C1 to C9 alkyl;
R4 is C1 to C6 alkyl; n is from 0 to 4; R5 and R6 are independently selected from hydrogen; C1 to C6 alkyl; the substituted alkanoyl group of formula III
10 11 12 III
Figure imgf000072_0002
wherein R10, R11 and R12 are independently selected from C1 to C4 alkyl and hydrogen; and wherein R5 to R6 may form a spiro-carbocyclic ring by the bridging group of formula II a
II a
Figure imgf000072_0001
wherein R10 and R11 are independently selected from hydrogen and C1 to C4 alkyl.
6. A compound according to claim 4 or claim 5 whereint
R1 is selected from the group consisting of C1 to C18 alkyl; C1 to C6 alkyl substituted with a substituent selected from C1 to C6 alkanoyl and (C1 to C6 alkoxy) carboxyl; C1 to C18 alkenyl; phenyl, and benzyl;
R2 is hydrogen or C1 to C4 alkyl; and wherein R1 and R2 may form a carbocyclic ring by the bridging group of formula
-CH2(CR7R8)CH2-
wherein R7 and R8 are independently selected from hydrogen and C1 to C 4 alkyl; R3 is selected from the group consisting of C2 to C18 alkyl; C1 to C9 alkyl substituted with a substituent selected from the group consisting of hydroxy and C1 to C9 alkoxy; C1 to C18 alkenyl; benzoyl; benzyl; benyoyl substituted with a substituent selected from C1 to C6 alkyl and C1 to C6 alkoxy; and C3 to C9 alkanoyl; R4 is C1 to C4 alkyl n is a from 0 to 3.
R5 and R6 are selected such that they comply with one of the possibilities selected from the group consisting oft (i)R5 and R6 are independently selected from hydrogen and C1 to C4 alkyl, (ii) one of R5 and R6 is hydrogen and the other is a group of formula III.
III
Figure imgf000073_0001
wherein R10, R11 and R12 are independently selected from the group consisting of hydrogen and C1 to C4 alkyl; and (iii) the group wherein R5 and R6 form a spiro carbocyclic ring by the diradical group of formula Ila.
11 Ila
Figure imgf000073_0002
wherein R10 and R11 are independently selected from the group consisting of hydrogen and C1 and C4 alkyl.
7. A compound according to any one of claims 4 to 6 inclusive whereint
R1 is C1 to C9 alkyl;
R2 is selected from hydrogen and C1 to C4 alkyl;
and wherein R1 and R2 may form a carbocyclic ring by the bridging group of formula
-CH2(CR7R8)CH2-
wherein R7 and R8 are independently selected from hydrogen and methyl;
R is selected from C2 ato C9 alkyl; C2 to C9 alkenyl; C1 to C9 alkyl substituted with a substituent selected from hydroxy, phenyl and C1 to C6 alkoxy; benzoyl; benyoyl substituted with a substituent selected from the group consisting of C1 to C6 alkyl and C1 to C6 alkoxy; and C3 to C9 alkanoyl;
R4 is selected from C1 to C4 alkyl;
n is from 0 to 3;
R5 and R6 are selected such that they comply with one of the possibilities selected from the group consisting of
(i) R5 and R6 are independently selected from hydrogen and C1 to C4 alkyl;
(ii) one of R5 and R6 is hydrogen and the other is a group of formula III ; III
Figure imgf000075_0002
wherein R10 and R11 are methyl and R12 is hydrogen or C1 to C9 alkyl; and
(iii) the group wherein R5 and R6 form a spiro carbocyclic ring by the diradical group of formula Ila
CH (CRR C II a
Figure imgf000075_0001
wherein R10 and R11 are methyl; and wherein when one of R5 and R6 is not hydrogen or C1 to C4 alkyl then n is zero.
8. A compound according to any one of claims 4 to 6 inclusive whereint
R1 is selected from the group consisting of
C1 to C9 alkyl;
R2 is hydrogen; and wherein
R1 and R2 may form a carbocyclic ring by the bridging group of formula
- CH2(CR7R8)CH2-
wherein R7 and R8 are methyl; R3 is selected from the group consisting of C1 to C9 alkyl; 2-phenylethyl and cyclohexyl;
R4 is methyl
n is chosen from 0 to 3;
R5 and R6 are selected such that they comply with one of the possibilities selected from the group consisting of (i) R5 and R6 are independently selected from hydrogen and methyl; (ii) one of R5 and R6 is hydrogen and the other is a group of formula III .
(CR10R11)CH2COR12 III
Figure imgf000076_0002
wherein R10 and R11 are methyl and R12 is ethyl; and
(iii) the group wherein R5 and R6 form a spiro carbocyclic ring by the diradical group of formula Ila.
II a
Figure imgf000076_0001
wherein R10 and R11 are methyl;
and wherein when at least one of R5 and R6 is not hydrogen or methyl then n is zero.
9. A compound of formula I(a)(i)
I (a) (i)
Figure imgf000077_0001
wherein R3, R4, R5, R6, R7, R8, and n are as herein defined with reference to any one of claims 4 to 8 inclusive.
10 A compound of formula
I (a)(ii)
Figure imgf000077_0002
wherein R3, R5, R6, R7 and R8 are as hereinbefore defined according to any one of claims 4 to 8 inclusive.
11. A compound according to claim 10 wherein
R 5 and R6 are selected such that either
(a) R and R form a carbocyclic ring by the diradical group of formula Ila (CR10 R11) Ila
Figure imgf000078_0003
wherein R10 and R11 are independently- selected from hydrogen and C1 to C4 alkyl; or
(b) one of R5 and R6 is hydrogen and the other is the group of formula IlIa
(CR10 R11) III a
Figure imgf000078_0002
wherein R10, R11 and R12 are independently selected from hydrogen and C1 to C4 alkyl.
12. A compound according to claim 11 wherein in each group of formula Ila and Ilia the groups R10 and
R11 are both methyl and R12 is ethyl.
13. A compound of formula
Figure imgf000078_0001
where R5 and R6 are independently selected from the group consisting of hydrogen, C1 to C6 alkyl and C1 to C6 alkoxy and R1, R2 R3, R4 and n are as defined according to any one of claims 4 to 8 inclusive.
14. A compound according to claim 13 wherein R5 and R are independently selected from hydrogen and C1 to C6 alkyl.
15. A compound according to claim 14 wherein R5 and R8 are hydrogen.
16. A compound according to any one of claims 4 to 6 whereint
R1 is selected from the group consisting of C1 to
C18 alkyl;
R2 is hydrogen;
R3 is selected from the group consisting of C2 to
C18 alkyl and C2 to C18 alkenyl;
n is 0;
R5 and R6 are hydrogen.
17. A compound according to claim 13 wherein:
R1 is selected from the group consisting of methyl, ethyl, propyl, 3-methylbutyl;
R2 is hydrogen;
R3 is selected from the group consisting of propyl,
1-methylethyl, butyl, 3-methylbutyl, 2-ethylhexyl, and 3-methyl-2-butenyl; n is 0; and
R5 and R6 are hydrogen.
18. A compound selected from the group consisting of
methyl 1-(3-methylbutyl)-1,4,5,6-tetrahydro-3-pyridyl ketone; methyl 1-(3-methyl-2-butenyl)-1,4,5-6-tetrahydro-3-pyridyl ketone; ethyl 1-butyl-1,4,5,6-tetrahydro-3-pyridyl ketone; ethyl 1-(3-methylbutyl)-1,4,5,6-tetrahydro-3-pyridylketone; propyl 1-propyl-1,4,5,6-tetrahydro-3-pyridyl ketone; propyl 1-butyl-l,4,5,6-tetrahydro-3-pyridylketone; propyl-1-(3-methylbutyl)-1,4,5,6-tetrahydro-3-pyridylketone;
4-methylpentyl 1-propyl-l,4,5,6-tetrahydro-3-pyridylketone; phenyl 1-propyl-1,4,5,6,-tetrahydro-3-ρyridyl ketone; and methyl 1-butyl-4,4,6 trimethyl-1,4,5,6-tetrahydro-3-pyridyl ketone.
19. A process for preparing a compound of formula I according to any one of claims 3 to 16 which process comprises eithert
(a) reducing the compound of formula V to give a compound of formula I having the formula I (c); or
(b) reacting the compound of formula IV with a compound of formula VI
Figure imgf000081_0001
20. A process according to claim 18 comprising
(a) Reacting the compound of formula VII with the compound of formula VI to provide a compound of formula V and reducing the compound of formula V to provide a compound of formula I having the formula I (c) ; or (b) Reducing the compound of formula VII to provide a compound of formula IV and reacting the compound of formula IV with a compound of formula VI to provide a compound of formula I having the formula I (e) .
Figure imgf000082_0001
VII
21. A sunscreen composition according to any one of claims 1 to 3 inclusive wherein the compound of formula I is as defined according to one of claims 4 to 17 inclusive.
22. A sunscreen composition according to any one of claims selected from the group of claims 1 to 3 and claim 21 wherein the compound of formula I comprises in the range of from 0.5 to 20% by weight of the total sunscreen composition.
23. A method of screening a surface from ultraviolet radiation the method comprising applying to the surface a composition according to any one of the claims selected from the group of claims 1 to 3, Claim 21 and Claim 22.
24. A method according to claim 21 wherein said surface is the surface of skin.
25. A compound according to any one of claims 4 to 17 inclusive substantially as herein described with reference to any one of Examples 1 to 36 inclusive.
PCT/AU1987/000330 1986-09-26 1987-09-25 Sunscreen compositions and compounds for use therein WO1988002251A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE87906641T DE3788568T2 (en) 1986-09-26 1987-09-25 SUN PROTECTION PREPARATIONS AND CONNECTIONS THEREOF.
AT87906641T ATE98863T1 (en) 1986-09-26 1987-09-25 SUNSCREEN PREPARATIONS AND CONNECTIONS THERETO.

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPH8208 1986-09-26
AUPH820886 1986-09-26
AUPH9230 1986-11-28
AUPH923086 1986-11-28
AU80728/87A AU595075C (en) 1986-09-26 1987-09-25 Pyridine derivatives and their use in sunscreen compositions

Publications (1)

Publication Number Publication Date
WO1988002251A1 true WO1988002251A1 (en) 1988-04-07

Family

ID=27156395

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1987/000330 WO1988002251A1 (en) 1986-09-26 1987-09-25 Sunscreen compositions and compounds for use therein

Country Status (1)

Country Link
WO (1) WO1988002251A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR900100129A (en) * 1989-02-23 1991-06-28 Ici Australia Operations Compositions and compounds absorbing ultra violet liqht
US5637718A (en) * 1989-02-23 1997-06-10 Ici Australia Operations Proprietary Ltd. UV-absorbing compounds
US7550482B2 (en) 2004-02-27 2009-06-23 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
US7598384B2 (en) 2004-02-27 2009-10-06 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
WO2015006803A1 (en) * 2013-07-15 2015-01-22 Coral Sunscreen Pty Ltd Uv absorbing compounds, compositions comprising same and uses thereof
WO2017088031A1 (en) * 2015-11-27 2017-06-01 Commonwealth Scientific And Industrial Research Organisation Photostable compounds, absorbing compounds and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1064116A (en) * 1963-04-03 1967-04-05 Aspro Nicholas Ltd Ultra-violet absorbing compositions
US4070450A (en) * 1974-04-18 1978-01-24 Hoffmann-La Roche, Inc. Sunscreening compound and method
EP0207287A2 (en) * 1985-06-04 1987-01-07 Bayer Ag Indole derivatives, process for their preparation and cosmetic preparation containing them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1064116A (en) * 1963-04-03 1967-04-05 Aspro Nicholas Ltd Ultra-violet absorbing compositions
US4070450A (en) * 1974-04-18 1978-01-24 Hoffmann-La Roche, Inc. Sunscreening compound and method
EP0207287A2 (en) * 1985-06-04 1987-01-07 Bayer Ag Indole derivatives, process for their preparation and cosmetic preparation containing them

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR900100129A (en) * 1989-02-23 1991-06-28 Ici Australia Operations Compositions and compounds absorbing ultra violet liqht
US5637718A (en) * 1989-02-23 1997-06-10 Ici Australia Operations Proprietary Ltd. UV-absorbing compounds
US7550482B2 (en) 2004-02-27 2009-06-23 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
US7598384B2 (en) 2004-02-27 2009-10-06 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
WO2015006803A1 (en) * 2013-07-15 2015-01-22 Coral Sunscreen Pty Ltd Uv absorbing compounds, compositions comprising same and uses thereof
JP2016526575A (en) * 2013-07-15 2016-09-05 コーラル サンスクリーン ピーティーワイ リミテッド UV-absorbing compounds, compositions containing the same and their use
AU2014292799B2 (en) * 2013-07-15 2017-03-30 Coral Sunscreen Pty Ltd UV absorbing compounds, compositions comprising same and uses thereof
WO2017088031A1 (en) * 2015-11-27 2017-06-01 Commonwealth Scientific And Industrial Research Organisation Photostable compounds, absorbing compounds and uses thereof
CN107108503A (en) * 2015-11-27 2017-08-29 联邦科学与工业研究组织 Photostabilised compound, absorption compound and application thereof
US10315994B2 (en) 2015-11-27 2019-06-11 Commomwealth Scientific And Industrial Research Organization Photostable compounds, absorbing compounds and uses thereof
CN107108503B (en) * 2015-11-27 2022-10-04 联邦科学与工业研究组织 Light stabilizing compound, absorbing compound and use thereof

Similar Documents

Publication Publication Date Title
US5328914A (en) Use of pyrimidine 3-oxide derivatives for slowing down hair loss and topical compositions used
KR101047242B1 (en) Whitening and external skin preparations
AU2010334642B2 (en) Phenol derivatives and pharmaceutical or cosmetic use thereof
EP0287603B1 (en) Sunscreen compositions and compounds for use therein
ES2290436T3 (en) USE OF 4-AMINOPIRIDINS FOR ANTIMICROBIAL SURFACE TREATMENT.
EP2210887A1 (en) Bis resorcinyl triazine derivatives as protecting agents against UV radiation
WO1988002251A1 (en) Sunscreen compositions and compounds for use therein
AU705235B2 (en) Photostable cosmetic light screening compositions
DE60019959T2 (en) USE OF BENZOTRIAZOLS AS UV ABSORBERS
EP3022180B1 (en) Uv absorbing compounds, compositions comprising same and uses thereof
US4070400A (en) Diphenyl polyamides having a cyclohexylene moiety
CA2962542A1 (en) Photostable compounds, absorbing compounds and uses thereof
AU2003254560B2 (en) Pyridyl-triazine derivatives as microbicidal active substances
EP0462123B1 (en) Uv-absorbing compounds and compositions
AU2007278245B2 (en) Use of aminophenylbenzotriazole derivatives for protecting human and animal skin and hair from the harmful effects of UV radiation and cosmetic compositions thereof
US4079059A (en) Diphenyl derivatives of polyamine compounds having a piperidine moiety
US10519111B2 (en) UV absorbing compounds, compositions comprising same and uses thereof
JP2982873B2 (en) 1,2-disubstituted benzenecarboxamide derivatives, hair restorer, external preparation for skin
JP2006503907A (en) Bisalkylbenzylamine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1987906641

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1987906641

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1987906641

Country of ref document: EP